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RIASSUNTO 
 
Il carcinoma epatocellulare (HCC) rappresenta la terza causa di morte per cancro nel 
mondo, con una stima di 564,000 nuovi casi nel 2000 e con un numero di decessi dello 
stesso ordine [1]. Nonostante  l’alcoolizzazione, la chemo-emobilizzazione o l’ablazione 
termica, le recidive locali sono la regola e l’aspettativa di vita breve. Il trapianto di un 
fegato sano costituisce il migliore approccio terapeutico, anche perchè le fasi avanzate di 
questo tipo di tumore, caratterizzate da una pronunciata ipervascolarizzazione e chemio-
resistenza, hanno quasi sempre una prognosi infausta.  
Il fattore eucariotico di elongazione (eEF1A) è una proteina che gioca un ruolo 
determinante nel processo di traduzione. E’ una GTP-binding protein, la cui funzione 
principale infatti è quella di reclutare l’amminoacil-tRNA e di trasportarlo sul sito A del 
ribosoma; per far ciò necessita di uno scambiatore di nucleotidi, eEF1B, e una molecola 
di GTP, che una volta idrolizzata permetterà il rilascio dell’amminoacil-tRNA sul 
ribosoma. eEF1A è codificata da solo due geni attivamente trascritti, rispettivamente 
EEF1A1 ed EEF1A2. Il primo mappa sul cromosoma 6q14.1, mentre il secondo sul 
cromosoma  20q13.3. Possiedono un’identità del 78% circa, mentre l’omologia di 
sequenza tra le due proteine è di circa il 92%. Nei Mammiferi eEF1A1 è espressa 
ubiquitariamente tranne nel tessuto scheletrico, cardiaco, nel cervello e nell’aorta, dove 
compare invece eEF1A2. eEF1A ha inoltre altre funzioni, definite non canoniche, in 
quanto è presente nei processi biochimici che regolano il citoscheletro, modulando la sua 
organizzazione durante il ciclo cellulare, in quanto ha due siti di legame per l’actina, uno 
all’N- e l’altro al C-terminale. 
 
 
 
Sono state prese in considerazione due linee cellulari tumorali: le HepG2, le e le JHH6, 
che rappresentano in vitro rispettivamente un modello di carcinoma epatocellulare ben 
differenziato e uno indifferenziato, onde capire quale possa esser il ruolo di eEF1A1 ed 
eEF1A2 nel carcinoma epatocellulare. 
Gli esperimenti di Real Time PCR indicano che si ha iperespressione di EEF1A1 e 
l’attivazione genica ed iperespressione di EEF1A2. I livelli di mRNA di eEF1A, 
paragonati a quelli del fegato normale, risultano infatti aumentati in entrambe le linee 
tumorali. L’iperespressione di questi geni dipende solo in parte dall’ amplificazione 
genica, in quanto si riscontra un modesto aumento nel numero dei geni. La maggior 
espressione di entrambe le forme di eEF1A nelle JHH6 trova conferma anche nei 
western blotting, dove si evidenzia un incremento di eEF1A nella linea JHH6 rispetto 
alle HepG2. 
Nonostante gli alti livelli espressi di questi due geni, i dati in nostro possesso indicano 
che eEF1A non conferisce alle linee tumorali JHH6 e HepG2 una protezione da apoptosi 
indotta dall’assenza di siero, nè influenza la proliferazione delle cellule sub-confluenti. 
Alti livelli di eEF1A sono invece correlabili con il mantenimento nel ciclo cellulare delle 
JHH6, rispetto alle HepG2, in condizioni di confluenza. Infatti, il saggio della 
senescenza associata a β-gal indica che già dopo due giorni dalla confluenza, la linea 
HepG2 va in senescenza in modo maggiore rispetto alla linea JHH6. Dopo quattro giorni 
dalla confluenza, le HepG2 sono quasi totalmente senescenti, mentre le JHH6 non 
mostrano  significativa attività di X-gal. 
Si possono fare diverse ipotesi per dare una spiegazione a questo fenomeno, una delle 
quali potrebbe essere che nella linea JHH6 i livelli più alti di eEF1A1 influenzerebbero 
l’organizzazione del citoscheletro e quelli di eEF1A2 del ciclo cellulare conferendo una 
 
 
 
 
maggior agressività a queste cellule sia in termini di motilità, che in termini di maggior 
resistenza a rimanere nel ciclo in condizioni estreme. 
Il bortezomib è un derivato dipeptidilico dell’acido boronico e fa parte di una nuova 
classe di antineoplastici definiti come “inibitori del proteasoma 26S”. Il proteasoma 26S 
è un complesso multienzimatico responsabile della degradazione via ubiquitina di 
proteine connesse con il ciclo cellulare, soppressori tumorali, oncogeni o inibitori 
correlati. Il bortezomib è il primo inibitore del proteasoma ad aver dimostrato una 
concreta efficacia terapeutica contro diverse neoplasie, tra cui alcune forme di leucemia 
mieloide, il mieloma multiplo (per cui ha già preso il via la sperimentazione clinica), i 
tumori della prostata, colon, polmone, ovaia, pancreas ed il melanoma. Non esistono 
tuttavia dati sulla sua possibile applicazione nei tumori epatici, nonchè attraverso quale/i 
meccanismo/i possa agire tale molecola. Le tre linee cellulari prese come modello di 
epatocarcinoma in vitro, sono state la linea HepG2, la linea HuH7 e la linea JHH6 che 
presentano un fenotipo simil-epatocitario per la prima, poco differenziato per la seconda 
ed epiteliode indifferenziata per la terza. Questo ci ha permesso di valutare se gli effetti 
del bortezomib potevano esser diversi in base al grado di differenziazione delle cellule 
tumorali epatiche. 
I dati in nostro possesso indicano che il bortezomib agisce sul proteasoma 20S (subunità 
catalitica del proteasoma 26S) nelle linee di epatocarcinoma considerate e riduce il 
numero di cellule vitali con un meccanismo dose-dipendente. Il suo meccanismo 
d’azione nelle linee da noi esaminate si esplica a livello del ciclo cellulare che viene 
alterato, innescando solo in minor parte la morte cellulare programmata. La risultante è 
quindi un effetto di blocco della proliferazione più evidente nelle HepG2 e nelle HuH7, 
 
 
 
rispetto alle JHH6 (anche se l’andamento dell’inibizione del proteasoma 20S sembra 
esser molto simile). 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer and the fifth 
leading cause of cancer-related death worldwide. Various aetiologies have been related 
to HCC development, but the most relevant being chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infections, chronic alcohol consumption and, in certain 
geographical areas, aflatoxin B1 food contamination. Approximately 10% of HCC 
patients show no signs of hepatitis virus infection, alcoholic history or other defined 
causes, such as genetic hemochromatosis or α1-antitripsin deficiency. Although such 
environmental risk factors have been clearly defined, the distinct molecular events that 
occur during HCC development are still not fully understood. 
We investigated the oncogenic role of the two forms of eukaryotic Elongation Factor 1A 
(eEF1A1/2) in the biology of HCC, as they have been recently proposed as important 
players in the process of oncogenic transformation and progression. The tumorogenic 
potential of eEF1A1 is supported by the observation that its over-expression correlates 
with increased metastatic potential in mammary adenocarcinoma. The ectopic 
expression of eEF1A2 induces the transformation towards a malignant phenotype of 
mouse and rat fibroblast and its expression in a human ovarian cell line that does not 
express eEF1A2 confers a more aggressive neoplastic phenotype compared to the 
parental cell line. Finally, amplification of the genome region encoding for eEF1A2 
protein has been found in breast, colon and ovary tumors. 
Results in the HCC cell lines HepG2, HuH7 and JHH6, indicated that EEF1A1 and, in 
JHH6 only, EEF1A2 are over-expressed when compared to normal liver tissue and this 
only in part depends on gene amplification. Moreover, the increased nuclear-
 
 
 
enriched/cytoplasmic protein ratio of eEF1A and the marked raise of both gene 
expression detected in JHH6 do not relate with apoptosis resistance. Finally, we 
observed that the increased of eEF1A expression is associated with an higher 
proliferation capacity in the undifferentiated JHH6 under sub-optimal growth conditions 
only. 
Despite major efforts to improve diagnosis and treatment of HCC, therapeutic options 
remain limited. The main therapeutic strategies consists either of surgical resection of 
the tumor or of organ transplantation. However, most patients reach the late stages of the 
disease with liver cirrhosis, a condition for which surgery may no longer be indicated. 
Moreover, liver transplantation is limited by the number of donors. Other treatments 
such as alcohization, chemo-embolization or thermal ablation, do not prevent local 
recurrences and the life expectancy is short. Thus, the discovery of new therapeutic 
approaches is of clear clinical relevance. 
Bortezomib is a boronic acid dipeptide derivative belonging to a new class of anti-cancer 
drugs, defined as 26S proteasome inhibitors. 26S proteasome is a multicatalytic complex 
involved in ubiquitinated proteins degradation, and bortezomib exerts its specific 
activity inhibiting the chymotrypsin – like activity of 26S proteasome. In vitro, many 
tumour cell lines have been shown to be susceptible to bortezomib-induced cell cycle 
arrest or cell death, while in vivo phase II and III clinical trials have been conducted in 
multiple myeloma and non-Hodgkin’s lymphoma affected patients, demonstrating 
increased survival rate in bortezomib-treated patients compared to controls. 
Despite the broad anti-cancer potential of bortezomib, little informations are available 
with regard to its effects on HCC. For these reasons, bortezomib effects on 
hepatocellular carcinoma cells was investigated. 
 
 
 
 
Our data show the mechanisms regulating cell toxicity and proliferation inhibition 
effects of bortezomib on the HCC cell lines JHH6 and HuH7, expanding the knowledge 
on HepG2. The different phenotypes, hepatocyte-like for HepG2, low differentiated for 
HuH7 and undifferentiated for JHH6, together with the less overall effect of bortezomib 
on JHH6, suggests that in vivo not all HCC forms may respond similarly to bortezomib 
treatment. Despite this fact, the potent pro apoptotic effect reported, the cytotoxic and 
anti-proliferative actions here described together with the in vitro observed negligible 
toxicity on normal human hepatocytes, make of bortezomib an attractive candidate for 
future experimentation in animal models, alone or in combination with specific 
molecular-targeted drugs, such as siRNA, possibly leading to a novel treatment for 
HCC.  
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1.1 The Hepatocellular Carcinoma 
1.1.1 Distribution of HCC 
Hepatocellular carcinoma (HCC) is among the most frequent type of liver cancer 
worldwide. At present, approximately 550000 new patients are diagnosed with HCC each 
year worldwide. However, regional differences in the incidence of HCC are significant 
(Fig. 1). The highest prevalence is found in southeast Asia and in the sub-saharian Africa, 
mostly due to the high rates of chronic viral hepatitis B and C (HBV and HCV), a high 
risk factors for HCC development. Additional causes linked to HCC are abuse of alcohol 
consumption, in certain geographical areas aflatoxin B1 food contamination, genetic 
hemocromatosis or α1-antitripsin deficiency [1-4]. 
 
Figure 1. Distribution of hepatocellular carcinoma.  
As evidenced, southeast Asia and sub-saharian Africa have the highest incident of HCC.  
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1.1.2 Hepatitis virus B and C 
HBV and HCV represent a major risk factor for developing of hepatocellular carcinoma. 
HBV (Fig. 2) infection is associated with about 40% of all HCC cases worldwide and 
most of the HBV-related HCCs contain viral DNA sequences integrated in human 
genome. Consequences of random and variable integrations reported are translocation, 
inverted duplication and recombination [5]. As consequence of these genomic alterations, 
some cellular regulatory genes could get lost.  
 
 
Figure 2. Hepatitis B virus model.  
Hepatitis B virus (HBV) is a member of theHepadnavirus family. The virus 
particle consists of an outer lipid envelope and an icosahedral nucleocapsid 
core composed of protein. The nucleocapsid encloses the viral DNA and a 
DNA polymerase that has reverse transcriptase activity. The outer envelope 
contains embedded proteins which are involved in viral binding of, and entry 
into, susceptible cells. The virus is one of the smallest enveloped animal 
viruses with a diameter of 42 nm. 
 
 
It was reported that the HBx viral gene seems to play a more causal role in HBV-related 
HCC, because it is the most commonly integrated viral gene [6, 7]. HBx protein acts as 
transcriptional transactivator of viral genes, via the modulation of RNA polymerase II and 
III; moreover, it affects the cellular DNA repair system. HBx protein acts also as co-
transcription factor for the major histocompatibility complex (MHC), deregulates cell 
cycle checkpoint controls and oncogenes like c-myc, c-jun/fos. These effects may alter 
host gene expression and lead to development of hepatocellular carcinoma. [6].  
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Compared to HBV-related hepatocarcinogenesis, much less is known about HCV-related 
liver damage (Fig. 3A and 3B). None of the different parts of the HCV genome is 
integrated into the host genome.  
 
 
 
Figure 3. 
A) Hepatitis C virus model. 
Hepatitis C virus (HCV) is a small (55-65 nm in size), enveloped, positive sense single strand RNA virus in the family Flaviviridae. 
The structure of the hepatitis C virus consists of a core of genetic material (RNA), surrounded by an icosahedral protective shell of 
protein, and further encased in a lipid (fatty) envelope of cellular origin. Two viral envelope glycoproteins, E1 and E2, are embedded in 
the lipid envelope. 
B) Cirrhosis development. 
Cirrhosis is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrous scar tissue as well as 
regenerative nodules (lumps that occur as a result of a process in which damaged tissue is regenerated), leading to progressive loss of 
liver function. Macroscopically, the liver may be initially enlarged, but with progression of the disease, it becomes smaller. Its surface is 
irregular, the consistency is firm and the colour is often yellow (if associates steatosis). Microscopically, cirrhosis is characterized by 
regeneration nodules, surrounded by fibrous septa. In these nodules, regenerating hepatocytes are disorderly disposed. Portal tracts, 
central veins and the radial pattern of hepatocytes are absent. Fibrous septa are important and may present inflammatory infiltrate 
(lymphocytes, macrophages) 
 
It was demonstrated that HCV-related core protein indirectly activate the TNF-α receptor, 
the Raf-1 kinase and NF-κB pathways leading to inhibition of TNF-α-induced and Fas-
mediated apoptosis [8-10]. These events might explain the development of liver 
carcinogenesis. 
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To gain better insight into HCV-related hepatocarcinogenesis, the microarray technology 
has been used in several studies. Honda et al. [11] and Shackel et al. [12] analyzed HCV 
cirrhosis and showed an up-regulation of pro-inflammatory, pro-apoptotic, and pro-
proliferative genes, which might reflect groups of genes being involved in HCV-related 
cirrhosis during progression to HCC. Dou et al. [13] analyzed gene expression profiles of 
the HCV genotypes 1b, 2a, and 4d core proteins in HepG2 and HuH7 cells. The authors 
found that each core protein has its own expression profile and that each of them seems to 
be implicated in HCV replication and oncogenesis [13, 14]. 
 
1.1.3 Genomic instability of HCC 
Recent studies have revealed a common genomic instability in human HCC. Conventional 
and array-based comparative genomic hybridization (aCGH) have been identified frequent 
DNA copy number gains at 1q, 6p, 8q, 17q, and 20q and losses at 1p, 4q, 8p, 13q, 16q, 
and 17p in HCC. Although target genes such as RB1 (13q14) and TP53 (17p13) have been 
identified and validated, the most part of altered loci remains unknown. Several aCGH 
studies have tried to identify chromosomal aberrations specifically related to HCC 
aetiology [15]. 
 
1.1.4 The Wnt pathway and HCC 
The Wnt signalling pathway has been studied extensively with respect to cancer 
development and differentiation [16-19]. Several lines of evidence support an essential 
role of the Wnt/β-catenin signalling pathway in HCC. These include an increased  
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expression and nuclear accumulation of β-catenin as a feature of an activated Wnt 
signalling pathway [16, 20, 21]. Up to 62% of all HCC were shown to display such a 
deregulation of β-catenin. In addition, a multivariate analysis has demonstrated poorer 
prognosis and higher rate of tumour recurrence in patients with nuclear accumulation of β-
catenin [20, 21]. 
Further attention was drawn to Wnt-/β-catenin-signalling when oncogenic β-catenin 
mutations were demonstrated to promote also the development of HCC. These mutations 
prevent β-catenin from being phosphorylated and thus prevent its degradation, resulting in 
activation of Wnt-/β-catenin signalling [22-24]. In addition, mutations of Axin1, a 
negative regulator of the Wnt signalling pathway, have also been reported to be highly 
prevalent in human HCC and transfection of wild type Axin1 lead to reconstitution of Wnt 
signalling and apoptosis in cancer cells [25, 26]. At a lower frequency, Axin2 mutations 
may contribute to HCC as well [27]. A liver-specific disruption of the APC gene in mice 
resulted in an activation of the Wnt-/β-catenin pathway and also in the development of 
HCC [28]. 
 
1.1.5 The Transforming Growth Factor β and HCC 
Elevated expression levels of TGFβ in HCC tissues have been found by means of 
Northern blot and immunohistochemistry [29-31]. Expression of TGF-β1 in HCC tissue 
was correlated with poorer histological differentiation [31]. In addition, serum and urine 
TGFβ levels have been shown to correlate with poorer prognosis and increased tumour 
angiogenesis [32-34]. Furthermore, it has recently been described in several tumour  
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entities that during tumour progression [35, 36]. TGFβ activity continues to be increased 
due to autostimulation of the Tgfb1 gene and due to transcriptional activation by Ras and 
other effectors, as well as by the action of proteases that activate the latent TGFβ in the 
extracellular matrix [37, 38]. 
 
1.1.6 Ras family and HCC 
Overexpression of Ras and members of the signalling pathway such as p21waf1/cip1 have 
been demonstrated in HCC [39, 40]. The three human ras genes (H-ras, N-ras and K-ras) 
encode for four proteins that function as small guanosine triphosphate (GTP) binding 
proteins, H-Ras, N-Ras, K-Ras4A and K-Ras4B [41-44]. The two forms of K-Ras only 
differ in their C-terminal 25 amino acids due to alternative splicing. Ras proteins are 
localized at the inner surface of the plasma membrane, where they serve as molecular 
switch to transduce extracellular signals into the cytoplasm to control signal transduction 
pathways that influence cell growth, differentiation and apoptosis [45]. Ras proteins can 
be activated by a wide range of extracellular proteins. For example, Ras proteins become 
activated following triggering of receptor tyrosine kinases such as the epidermal growth 
factor receptor (EGFR) [46]. 
Single amino acid substitutions at N-ras codon 12, H-ras codon 13 or K-ras codon 61, that 
unmask Ras transforming potential, create mutant proteins that are insensitive to GAP 
(Ras p120 GTPase Activation Protein) stimulation [47]. Consequently, these oncogenic 
Ras mutant proteins are locked in the active, GTP-bound state, leading to constitutive, 
deregulated activation of Ras function. Likewise, inhibitors of the Ras pathway were  
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reported to be down-regulated in HCC [48]. Besides overexpression of Ras in HCC, 
mutations of the Ras proto-oncogenes, locking Ras in the active state, have been 
identified. The most commonly investigated mutations were the N-Ras codon 61 [49-51], 
the H-Ras codon 12 [52] and the K-Ras codon 12 mutation [53-55].  
Ras mutations were continuously observed in HCC induced by various chemical agents in 
rats. These chemicals inducing HCC were N-nitrosomorpholine (NNM) [56], a 
combination of bleomycin and 1-nitropyrene [53], methyl (acetoxymethyl) nitrosamine 
[57], acetylaminofluorene (AAF) [140], 3-methyl-(dimethylamino) azobenzene [58], and 
nitroglycerine [59]. In accordance with these data originating from murine HCC models, 
tumour tissue of workers exposed to vinyl chloride were demonstrated to contain a 
significant level of Ras mutations, supporting evidence for a role of Ras mutations in HCC 
[60, 61]. As a consequence of the overexpression of the Ras pathway in HCC and in order 
to identify novel therapeutic targets for the treatment of HCC, various groups have lately 
studied regulation of the pathway by antisense RNA. Thereby, it has been reported that the 
antisense treatment for H-Ras significantly inhibited hepatocarcinogenesis and was able to 
reconstitute apoptosis [56, 62, 63]. In addition, novel therapeutic approaches using 
multikinase inhibitors such as sorafenib which targets Raf kinase in patients with 
advanced HCC, have displayed a moderate therapeutic efficacy as a single-agent and may 
now be evaluated for combination treatment with other anticancer agents [64]. 
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1.1.7 The role of Retinoblastoma protein in HCC 
Although a vast amount of data has been accumulated on the role of Retinoblastoma 
protein (Rb) in cancer differentiation for several cancer entities, only limited insight is 
available on a role of Rb in HCC differentiation. 
The tumour suppressor retinoblastoma protein, is critical for the development of several 
cancer types. Rb is the target for phosphorylation by several kinases. In normal cell 
signalling, Rb prevents cell division and cell cycle progression [65]. Bound to the 
transcription factor E2F, Rb acts as a growth suppressor and prevents progression through 
the cell cycle [66]. Rb inhibits cell cycle progression only in the hypo-phosphorylated 
state, binding the transcription factor E2F [66]. 
Before entering S-phase, complexes of a cyclin-dependent kinases (CDK) and cyclins 
phosphorylate Rb [65-69]. Subsequently, phosphorylation of Rb results in the dissociation 
of E2F-DP from Rb [65, 66]. Free E2F can then activate cell cycle factors, leading to 
progression of the cell cycle (Fig. 4). Thus, cells with mutated Rb are subject to reduced 
control in cell cycle progression one of the hit required for the development of cancer. 
Rb has been demonstrated to be inactivated in human HCC cell lines and in 28% of HCCs 
[70]. Simultaneously, additional members of the Rb network also have significantly 
aberrant expression in HCC. For example cyclin D1/CdK4, which inactivates Rb by 
phosphorylation, is over-expressed in 58% of HCCs [71]. Furthermore, the p16ink4a 
protein, a regulator of Rb activity through inhibition of CdK4, is absent in 34% of HCCs 
[72]. Together, these data suggest that disruption of the Rb regulatory pathway is common 
in HCC carcinogenesis. 
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1.2 The cell cycle 
1.2.1 Cell cycle phases 
The cell cycle consists of four distinct phases: G1 phase, S phase (synthesis), G2 phase 
(collectively known as interphase) and M phase (mitosis). M phase is itself composed of 
two tightly coupled processes: mitosis, in which the chromosomes are divided between the 
two daughter cells, and cytokinesis, in which the cytoplasm divides forming distinct cells. 
Activation of each phase is dependent on the proper progression and completion of the 
previous one. Cells that have temporarily or reversibly stopped dividing are said to have 
entered in a state of quiescence, called G0 phase. Although the various stages of interphase 
are not usually morphologically distinguishable, each phase of the cell cycle has a distinct 
set of specialized biochemical processes that prepare the cell for initiation of cell division. 
Regulation of the cell cycle involves ordered and directional processes crucial to the 
survival of a cell, including the detection and repair of genetic damages as well as the 
prevention of uncontrolled cell division [73]. 
 
1.2.2 Cell cycle regulators 
Two key classes of regulatory molecules, cyclins and cyclin-dependent kinases (CdKs), 
determine the cell progression through the cell cycle [74, 75].  Cyclins form the regulatory  
subunits and CdKs the catalytic subunits of an activated heterodimer; cyclins have no 
catalytic activity and CdKs are inactive in the absence of a cyclin partner. When activated 
by a bound cyclin, CdKs activates target proteins to orchestrate coordinated entry into the 
next phase of the cell cycle. CdKs are constitutively expressed in cells whereas cyclins are  
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synthesised at specific stages of the cell cycle, in response to various molecular signals. 
Cyclin D is the first cyclin produced in the cell cycle, in response to extracellular signals 
(eg. growth factors) [76, 77]. Cyclin D binds to existing CdK4, forming the active cyclin 
D-CdK4 complex. Cyclin D-CdK4 complex in turn phosphorylates the retinoblastoma 
protein (pRB) [78]. The hyperphosphorylated pRB released active E2F/DP complex. 
Activation of E2F results in transcription of various genes like cyclin D, cyclin E, cyclin 
A, CdKs, etc. [79]. Cyclin E thus produced binds to CdK2, forming the cyclin E-CdK2 
complex, which pushes the cell from G1 to S phase (G1/S transition). Cyclin B along with 
CdK1 forms the cyclin B-CdK1 complex, which initiates the G2/M transition [73, 80, 81]. 
 
1.2.3 Cell cycle inhibitors 
Two families of genes, the INK4/ARF (Inhibitor of Kinase 4/Alternative Reading Frame) 
and the CIP/KIP inhibit the progression of the cell cycle [70, 82, 83]. The INK4/ARF 
family include p16ink4a, which binds to CdK4 and arrests the cell cycle in G1 phase, and 
p14arf which prevents p53 degradation. The CIP/KIP family includes the cell cycle 
inhibitors p21waf1/cip1, p27kip1 and p57kip2. They inhibit cell cycle in G1/S phase, by binding 
to, and inactivating, cyclin-CdK complexes. p21waf1/cip1 can be activated also by p53, while 
p27kip1 is activated by Transforming Growth Factor β (TGF β) [80]. A summary of cell 
cycle is reported in Figure 4. 
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Figure 4. Cell cycle summary and 
related factors. 
Here are reported the main factors 
related to cell cycle activation (Cyclin 
D, CdK 4/6, E2F), progression (Cyclin 
E, cyclin E, cyclin A, CdK 1/2, E2F) 
and inhibition (p16ink4a, p21waf1/cip1, 
p27kip1, Rb). 
 
 
 
1.3 The Eukaryotic Elongation Factor 1A 
1.3.1 Role in protein elongation 
The eukaryotic elongation factor 1A (eEF1A, eEF1α) catalyzes the first step of the 
elongation cycle [84, 85] It carries the aminoacyl-tRNA (aa-tRNA) on the A site of the 
ribosome which contains the growing polypeptide chain as peptidyl-tRNA in the P site. 
The aa-tRNA is carried on the ribosome as a ternary complex eEF1A-GTP-(aa-tRNA) 
and, following the hydrolysis of GTP, the eEF1A-GDP leaves the ribosome. This event 
allows the correct positioning of aa-tRNA in the A site of the ribosome in response to a 
correct codon-anticodon recognition. The second step of the elongation cycle involves the  
regeneration of the inactive GDP-bound form of eEF1A into the active GTP-bound form 
through an exchange reaction catalysed by the exchange factor 1Bα (eEF1Bα). After the 
formation of a new peptide bond catalysed by the ribosomal peptidyltransferase, a 
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peptidyl-tRNA is present on the A site of the ribosome and a deacylated tRNA in the P 
site (ribosome in pre-translocative state). In the third step of the elongation cycle, 
translocation, the elongated peptidyl-tRNA moves from the A site to the P site of the 
ribosome. The reaction is catalysed by the elongation factor 2. Following the hydrolysis of 
GTP, the complex eEF2-GDP leaves the ribosome, thus ending the translocation reaction. 
The elongation cycle is so completed and the machinery is ready to initiate a new cycle 
(Fig. 5) [86]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Protein synthesis elongation cycle. 
Role of eEF1A, eEF1Bα and eEF2 in the first, second and third step of the elongation cycle, respectively. 
aa-tRNA=aminoacyl-tRNA, EF-1α=elongation factor 1A, EF-1β=elongation factor 1Bα; EF-2=elongation factor 2, A and P=ribosomal 
A and P site  
 
 
1.3.2 eEF1A1 and eEF1A2 
In mammals several eEF1A-genes are present, but only two forms, termed eEF1A1 and 
eEF1A2, are actively transcribed. Human EEF1A1 has been mapped on chromosome 
6q14, while human EEF1A2 has been mapped on 20q13.3 [87]. The two proteins are 92% 
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identical at the aminoacid level and display equal activities in an in vitro translation assay 
[88]. However, eEF1A1 is constitutively expressed in all known tissues except for skeletal 
muscle, whereas eEF1A2 expression appears to be limited to skeletal muscle, heart, brain 
and aorta [88, 89]. The transcription of eEF1A2 occurs concomitantly with a down-
regulation of eEF1A1, indicating that eEF1A2 takes over the function of eEF1A1 in 
protein syntesis in a tissue-specific manner [90, 91]. 
 
1.3.3 Non-canonical functions of eEF1A and cancer 
Beside the central role in protein translation, eEF1A is implicated in several biochemical 
processes including the interaction with the cytoskeleton [92, 93], apoptosis and cell 
proliferation. With regard to apoptosis, it has been shown that eEF1A2 ectopic over-
expression protects muscle cells from caspase-3 induced apoptosis [94], and its absence in 
mice results in an increased muscle cell apoptosis [95]. eEF1A1 protects also against 
apoptosis induced by IL-3 withdrawal [96], and the acquisition of cisplatinum resistance in 
human head and neck cancer cell line is associated to eEF1A1 over-expression [97]. 
eEF1A interconnection with cell proliferation derives from the observations that eEF1A 
levels directly correlates to cell cycling rate [98-100]. Additionally, redistribution from the  
cytoplasm to the nucleus of eEF1A was observed in proliferating compared to starved 
cells [92]. 
The eEF1A ability to modulate apoptosis and cell growth has strictly linked this protein 
with cancer. Recently, eEF1A has been implicated in the process of oncogenic 
transformation. The tumorogenic potential of eEF1A1 has been proposed following the 
observation that its over-expression correlates with increased metastatic potential in 
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mammary adenocarcinoma [101]. The ectopic expression of eEF1A2 induces the 
transformation towards a malignant phenotype of mouse and rat fibroblast [102] and its 
expression in a human ovarian cell line that does not express eEF1A2 confers a more 
aggressive neoplastic phenotype compared to the parental cell line [103]. Finally, 
amplification of the genome region encoding for eEF1A2 protein has been found in  
breast, colon and ovary tumors [104-106].  
 
 
1.4 The ubiquitin-proteasome pathway 
1.4.1 Introduction 
The ubiquitin-proteasome pathway is the primary mechanism for the disposal of damaged 
or unwanted proteins in the cells of eukaryotic organisms. Elimination of targeted 
regulatory proteins via this pathway is fundamental for the control of many essential cell 
functions, including cell cycle progression, gene transcription, signal transduction, 
inflammatory processes and apoptosis. The ubiquitin-proteasome protein degradation 
pathway (UPP) consists of ubiquitin, a three-enzyme ubiquitination complex, the 
intracellular protein ubiquitination targets, and the proteasome that is the organelle of 
protein degradation. The ubiquitination machinery is present both in the cytosol and in the 
nucleus [107, 108]. 
 
1.4.2 The UPP cascade  
The ubiquitin-activating enzyme, E1, initiates ubiquitin ligation by adenylating ubiquitin 
[109, 110]. One ATP molecule is expended for each E1-ubiquitin linkage. The ubiquitin 
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molecule is transferred to the ubiquitin-conjugated enzyme E2, which transiently carries 
ubiquitin. E2 works in conjunction with the ubiquitin E3 ligase, which is responsible for 
conferring substrate specificity on the reaction. E3 mediates the transfer of ubiquitin to an 
internal lysine of the target protein. The first conjugated ubiquitin serves as a basal 
information for a polyubiquitin chain, which constitutes the protein degradation signal. 
The polyubiquitinated target protein undergoes proteolytic cleavage by the proteasome, 
which is a large, cylindrical multisubunit complex. The hierarchical organization of the 
ubiquitin-proteasome enzymatic conjugation cascade places a single E1 enzyme at the top, 
that activates ubiquitin for all subsequent downstream reactions and all E2 enzymes [110]. 
At the next stage, there are many E2 ubiquitin-conjugated enzymes that have defined but 
with a broad specificity. The last phase of ubiquitination is mediated by the E3 family of 
ubiquitin ligases, which is largely responsible for target protein specificity. Each E2 
interacts with several E3s and each E3 targets with several substrates based on the shared 
recognition motifs. Each E3 can interact with more than one E2 and some substrates can 
be targeted by more than one E3 (Fig. 6) [111]. 
 
 
Figure 6. The ubiquitin E1-E2-E3 enzymatic cascade. 
 
A ubiquitin-activating enzyme (E1) binds ubiquitin in an adenosine 
triphosphate (ATP)-dependent step. Ubiquitin is then transferred to a 
ubiquitin-conjugated enzyme (E2). A ubiquitin ligase (E3) helps 
transfer ubiquitin to the target substrate. 
 
AMP=adenosine monophosphate 
PPi=pyrophosphate 
Ub=ubiquitin 
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1.4.3 The 26S proteasome 
1.4.3.1 Structure 
The 26S proteasome is a multisubunits protein complex and is the site for ATP-dependent 
degradation of ubiquitin-tagged proteins [112-114]. The structure and function of the 
proteasome are highly conserved from archaebacteria to eukaryotes [115, 116].  
The 26S proteasome is essentially a hollow cylinder-shaped particle formed by two major 
subunits that can assemble in an ATP-dependent manner [117, 118]. The 20S catalytic 
component contains multiple proteolytic sites, while the 19S regulatory components 
contain multiple ATPases and a binding site for ubiquitin concatamers (Fig. 7) [119]. 
 
 
Figure 7. Structure of 26S proteasome. 
 
The 19S regulatory particles attach to the outer 
surface of the 20S core particle. The 20S core 
particle contains four heptameric rings (two 
outer identical α rings and two inner identical β 
rings). The β rings of the 20S subunit harbour 
catalytic activity, and the 19S regulatory 
subunits function in substrate recognition, 
binding, and unfolding. 
 
ATP=adenosine triphosphate 
polyUb=polyubiquitination  
 
 
 
The 20S subunit is the core of the 26S proteasome and it is formed by four heptameric 
protein rings harbouring catalytic sites that face into the hollow centre of the ring structure 
[118, 120]. The 20S catalytic-β-subunits contain trypsin (β2), chymotrypsin (β5) and post-
glutamyl peptide hydrolase (β1)-like activities. The two α-rings sandwich the β-rings.  The 
amino terminus of the α-subunits blocks the access to the proteolytic chamber, so the inner 
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cavity of the proteasome is only available through the narrow pores on both ends of the 
cylinder [121].  
The 19S regulatory components assemble at each pore of the 20S subunit to form the 26S 
proteasome. The 19S subunits act as a gate agent limiting the entry of targeted proteins 
into the proteasome. The 19S subunits are also essential for proteolytic activity because 
the 20S subunit alone is inactive [111, 122]. A single 19S regulatory particle is composed 
of two substructures, a lid and base, involved in substrate selection, preparation and 
protein translocation into the catalytic chamber for degradation [122, 123]. Each 19S 
particle is composed of numerous subunits, including six ATPases, that most likely 
provide the energy necessary for substrate unfolding required before entry into the 20S 
chamber [124]. The outer-lid subcomplex of the 19S component is involved in the 
recognition and ubiquitin chain processing before substrate translocation and degradation 
[125, 126]. 
 
1.4.3.2 Degradation of Ub-proteins by 26S proteasome 
Proteins are degraded in a processive manner by the proteasome; thus, a single protein is 
hydrolyzed to final products before the next substrate enters [127]. This ordered process 
contrasts to the activity of cytosolic proteases that cleave proteins once before dissociating 
from their substrates. The average length  of the cleavage products in the proteasome 
varies from six to ten aminoacids; complete hydrolysis to individual aminoacids, occurs in 
the cytosol (Fig. 8) [128]. 
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Figure 8. The ubiquitin-proteasome pathway. 
Proteins marked with a polyubiquitin chain by the E1-E2-E3 
enzymatic cascade are targeted for degradation by the 
proteasome. Proteins degraded through proteasome average six 
to ten aminoacids in length, and eventual hydrolysis to 
individual aminoacids occurs in the cytosol. 
 
 
 
 
1.4.4 26S proteasome inhibitors 
Because the 26S proteasome occupies a critical position in the regulation of cellular 
processes, its inhibition is under investigation as a potential anticancer therapy. The 
dideptide boronic acid analogue bortezomib (Fig. 9A and 9B) is the first proteasome 
inhibitor to be evaluated in human studies [129-133]. 
 
 
Figure 9. Bortezomib formula. 
 
A) [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcabonyl) amino]propyl]amino]butyl]boronic acid.  
B) Tridimensional model of bortezomib structure. 
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The first compound with documented effects on proteasomal function was identified as 
non-peptidic Streptomyces metabolite lactacystin. Its intermediate clasto-lactacystin β-
lactone interferes with the β5-subunit (chymotrypsin-like activity) irreversibly by selective 
modification of amino-terminal threonine residues and reversibly with the β1-subunit 
(peptidylglutamyl-like activity) and β2-subunit (trypsin-like activity) [134, 135]. In the 
course of further characterizations of proteasome structure with x-ray crystallography, 
more selective and potent proteasome inhibitors were synthesized [136, 137]. They 
included tripeptide aldheydes, which inhibit reversibly β2- and β5- subunit by forming 
hemiacetal adducts with the active site of β-subunits. Moreover, they also inhibit thiol 
proteases like calpains and cathepsin B and display metabolic instability due to their 
configuration, so that poor specificity and bioavailability limit their utility in vivo. The 
next generation of proteasome inhibitors included boronic acid dipeptides like bortezomib, 
which are capable of building stable, but reversible, tetrahedrical intermediates with the 
amino-threonine residues of the catalytically active core complex of the 26S proteasome 
[136]. Bortezomib blocks the proteasome with a Ki value of 0,6 nM [138], with a 
restoration of proteasome activity within 24 hours [131]. This explains their slow 
dissociation from the proteasome in comparison to the aldehydes, the 1000-fold potency 
and the high sensitivity for chymotrypsin-like activities of the 26S proteasome. High 
selectivity, stability and low toxicity profile due to the reversibility of the proteasome 
inhibition, allowed bortezomib to enter clinical trials. 
 
1.4.5 Bortezomib affects cell cycle progression and apoptosis 
Cell division might be divided into 3 steps: DNA replication, mitosis and cytokinesis. In 
the G1/S phase of the cell cycle, the sister chromatids are separated and synthesis of the 
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complimentary DNA takes place. The ordered processing of only one round of DNA 
replication in each cell cycle requires exactly coordinated levels of positive and negative 
regulators, such as cyclins, cyclin-dependent kinases (CDK), CDK-cyclin complexes and 
cyclin-dependend kinase inhibitors of the Cip/Kip and INK4 families [139]. 
The G2/M phase of the cell cycle is responsible for proper localization of doubled 
chromosomes along kinetochore microtubules, division of sister chromatides and nuclear 
division. Cyclin B activates CDK1 and thus produces an active mitotic CDK-cyclin 
complex that promotes the entry into the prophase and consecutively the formation of 
mitotic spindle. Furthermore, the CDK-complex activates the anaphase-promoting 
complex/cyclosone (APC/C), which acts as a E3 ubiquitin ligase. APC catalyses the 
ubiquitination and thus initiates degradation of cyclin A and B, in order to ensure the 
completion of mitosis and re-enter into the next cell cycle [140]. Proteasome inhibition 
leads to stabilization and accumulation of both promoters and suppressors of the cell 
cycle. As a consequence, the cell receives aberrant signals thus getting arrested and 
activating the apoptotic program. 
Apoptosis is a highly conserved process that ensures the tissue development during 
embryonic organogenesis, postembryonic organ growth and development [141]. A 
complex network of molecular events governs the activation of enzymatic DNA-
fragmentation managed by caspases. The DNA degradation ultimately results in apoptosis. 
The direct mechanism of the 26S proteasome to generate anti-apoptotic signals and to 
promote survival is based on the observation that proteasome degrades pro-apoptotic 
proteins like Bax and Bid [142]. They both are members of the Bcl-2 family of apoptosis-
regulating proteins localized in the outer mitochondrial membrane and regulate 
mitochondrial release of cytochrome c, which is a sine qua non condition for the execution 
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of apoptosis. Stabilization of Bax and the disruption of the Bax/Bcl-2 balance, enhances 
the mitochondrial apoptosis in tumour cells [143]. Table 1 reports target proteins of 26S 
proteasome. 
 
Table 1. Target proteins of 26S proteasome. 
Class of protein Proteins Functions 
Bax, IAPs, MDM2 Promotion of apoptosis 
Apoptosis 
Bcl-2 Inhibition of apoptosis 
Cyclin A Cell cycle regulation during S and M phases 
Cyclin B Cell cycle regulation during M phase 
Cyclin D Cell cycle regulation during G1 phase 
Cyclins 
Cyclin E Cell cycle regulation during G1-S transition 
p21waf1/cip1 Cyclins dependent 
kinase inhibitors p27kip1 
Cell cycle regulation 
Inhibitors of 
transcriptional 
factors 
I-κB Inhibition of transcriptional factor NF-κB 
c-Fos/c-Jun, c-Myc Transcription factors 
Oncogenes 
Β-catenin Transcription regulator 
E2A Cellular growth and differentiation 
E2F Regulation of cell cycle genes 
Transcriptional 
factors 
STAT Transcription of cytokine-inducible genes 
p53 Apoptosis, cell cycle arrest, senescence Tumor suppressor 
proteins Rb Repressor of transcriptional factor E2F 
 
1.4.6 Bortezomib and Nuclear Factor-kappa B pathway 
Proteasome inhibitors drew clinical interest as potential antineoplastic agents owing to 
their ability to down-regulate the nuclear factor-kappa B (NF-κB) pathway, resulting in an 
anti-apoptotic and survival signals in neoplastic cells [144]. NF-κB is one of crucial 
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transcription initiators of various genes involved in cell proliferation and inflammation. 
Inactive NF-κB is found in cytoplasm, bound to its inhibitor IκB. IκB is a proteasomal 
substrate, which, after phosphorylation and ubiquitination, is degraded by the proteasome. 
Following IκB degradation, free NF-κB translocates into the nucleus promoting 
transcription of cytokines, growth factors and growth factor receptors (Fig. 10) [145, 146].  
NF-κB activation is observed in many malignant cells undergoing radio- or chemotherapy. 
The molecular mechanism involved in chemosensitization due to proteasome inhibition 
includes the inhibition of aberrant NF-κB activation. Specific inhibition of NF-κB 
sensitized cells to chemotherapy, demonstrating that NF-κB is a target for circumventing 
drug resistance [133]. 
Since proteasome inhibition has been shown to block NF-κB activation, this strategy has 
been examined in various preclinical studies in order to disrupt tumour drug resistance and 
enhance chemosensitivity. Bortezomib-induced reduction of NF-κB activation led to 
diminished transcription of anti-apoptotic molecules [147], as well as pro-survival 
cytokines.  
 
 
 
 
Figure 10. NF-κB pathway. 
 
Degradation of  NF-κB inhibithor, IκB, by ubiquitin-
proteasome pathway activates NF-κB that translocates 
into the nucleus promoting transcription of cytokines, 
cell adhesion molecules, anti-apoptotic and cell cycle 
related factors.   
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1.4.7 Potential therapeutic value of bortezomib 
In several in vitro and in vivo experiments many tumour cell lines have been shown to be 
susceptible to bortezomib-induced cell cycle arrest or cell death [148]. Pre-clinical studies 
have repeatedly demonstrated a selective susceptibility of transformed cells to proteasome 
inhibition [149]. Several group have explored the molecular basis by which proteasome 
inhibitors selectively mediate apoptosis in malignant cells and found that actively 
proliferating cells were more susceptible to proteasome inhibitor-mediated apoptosis than 
quiescent cells [150]. 
In human Bcr/Abl+ leukaemia cells resistant to imantinib (STI-1571, a protein kinase 
inhibitor), bortezomib induced synergistic apoptosis, when administered with cyclin-
dependen kinase inhibitor flavopiridol [151], further demonstrating the chemosensitizing 
effects of bortezomib. 
Exposure to bortezomib inhibits growth and causes apoptosis in cultured PC-3 prostate 
cancer cells  [152]; bortezomib increased also the potency of camptothecin-11 (CPT-11) 
and radiation against colon tumour xenograft [153]; in addition, it enhanced the 
antitumour effect of gemcitabine and CPT-11 against pancreatic tumour xenograft [154]. 
Finally, bortezomib exerts a pro-apoptotic effect by decreasing the levels of XIAP protein, 
a member of the inhibitor of apoptosis (IAP) family, in ovarian carcinoma cells [155]. 
Non-Hodgkin’s lymphoma (NHL) cells also appear to be affected by bortezomib. The 
agent has been shown to cause cell cycle arrest and rapid induction of apoptosis in mantle 
cell lymphoma (MCL) and primary effusion lymphoma (PEL) cells. As NF-kB is 
constitutively active in both these tumour types, inhibition of the NF-kB pathway by 
bortezomib may contribute to the apoptotic activity [149, 156]. In addition, bortezomib 
has been shown to induce apoptosis through the up-regulation of p21waf1/cip1, p27kip1 and 
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p53 in PEL cell lines [157]. The effectiveness of bortezomib in PEL cells is particularly 
significant, because these tumours, a rare subtype of NHL, are relatively resistant to 
standard cytotoxic chemotherapy [158]. Activity has also been demonstrated in cell 
samples derived from patients with MCL and patients with follicular lymphoma (FL). 
Using a primary culture system, bortezomib was found to be effective in cells from both 
NHL subtypes; MCL cells were significantly more sensitive to bortezomib than FL cells 
[159].  
Expression of cell cycle regulators has been identified in bortezomib studies as an early 
effect of proteasome inhibition; this is followed by down-regulation of cyclin D1 
expression and subsequent cell cycle arrest [156]. Bortezomib also demonstrated in vivo 
activity in MCL, suppressing cell growth and preventing the development of tumours in 
human MCL-xenografted mice [160]. Additionally, bortezomib has demonstrated potent 
inhibition of adult T-leukemia/lymphoma (ATLL) cell growth in in vitro and xenograft 
murine models [161]. The efficacy of bortezomib in several subtypes of NHL has been 
demonstrated in phase II clinical trials. A number of studies on bortezomib, both as a 
single agent and in combination with dexamethasone and doxorubicin, are ongoing or 
planned. Interim results indicate that bortezomib is well tolerated and active in NHL, with 
some durable response rates of 18-60% in FL and 39-56% in MCL. There is also 
preliminary evidence of drug activity in other subtypes of NHL, including marginal zone 
lymphoma (MZL) and Waldenström’s macroglobulinemia (WM) [162-164]. 
In multiple myeloma cell lines and freshly isolated patient myeloma cells, bortezomib 
could induce apoptosis irrespective of p53 status and despite p21waf1/cip1 and p27kip1 
induction, by inhibiting the mitogen-activated protein-kinase growth signalling and NF-κB 
signalling. NF-κB is constitutively active in myeloma cell lines and patient myeloma 
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samples [165]. Treatment of myeloma cell lines and patient samples with bortezomib 
resulted in growth inhibition, even in drug-resistant cell lines and correlates with I-κB 
stabilization and decrease of NF-κB activity. Interestingly, bone marrow stroma-mediated 
production of interleukin-6, a cytokine that plays an important role in myelomagenesis and 
whose transcription is up-regulated by NF-κB, was attenuated by bortezomib, 
demonstrating that proteasome inhibitors may achieve the anti-myeloma effects in part 
through modulation of the bone marrow microenvironment [166]. Bortezomib potently 
sensitizes myeloma cells to doxorubicin and melphalan, even in cases with confirmed 
resistance to these drugs by inhibiting genotoxic stress response pathways and thereby 
restoring sensitivity to DNA-damage induced by chemotherapeutic agents [167]. 
 
 
1.4.8 Multiple Myeloma treatment with bortezomib 
Recently, phase III trial for treatment of refractory multiple myeloma (MM) patients was 
performed. The study evaluated bortezomib and dexamethasone therapy in patients with 
MM relapsed after 1-3 prior therapies, and results revealed a highly significant difference 
in response rates (38% for bortezomib/18% for dexamethasone), benefit in time to 
progression and overall survival for patients who received bortezomib [168]. Bortezomib 
has now been approved by the United States Food and Drug Administration and the 
European Medicine Evaluation Agency for patients with relapsed or refractory multiple 
myeloma.  
In conclusion, bortezomib is the first proteasome inhibitor to enter human clinical trials, 
and results indicate that this drug may be particularly useful in anticancer therapy.  
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1.5 RNA interference pathway 
RNA interference (RNAi) is a post-transcriptional gene-silencing phenomenon that occurs 
in eukaryotic organisms. It is involved in development regulation, genome maintenance  
and immune response to viral and transposon expansion [169, 170]. It was most notably 
described in Caenorhabditis elegans by Andrew Fire, Craig Mello and their colleagues in 
1998 and represents an exciting development in the field of nucleic acid–based 
therapeutics [171]. 
The RNAi response is initiated when the guest cell encounters a long host dsDNA 
molecule-derived and it can be divided into two distinct steps. The first, called the 
assembly phase, comprises the recognition of a long dsRNA molecule and its processing 
by the RNase III-like enzyme Dicer into fragments of 19-21 nucleotides, termed short 
interfering RNAs (siRNAs). siRNAs are then incorporated into the RNA-induced 
silencing complex (RISC), a ribonucleoprotein composed of an Argonaute protein and a 
single-stranded guide RNA. The selection of the RNA strand that will be incorporated is 
governed by the thermodynamic profile of the siRNA duplex termini. 
In the second phase, also known as the effector phase, ATP-activated RISC uses this 
single-stranded RNA molecule as a guide to cleave complementary mRNAs. The cleavage 
products are released and degraded, leaving the siRNA-RISC complex to survey and 
further deplete the available pool of target mRNAs. Although RISC-mediated target RNA 
cleavage is very studied, the final steps of the assembly process of RISC are still a matter 
of debate, especially how the “guide” strand is separated from the passenger strand (Fig. 
11) [172, 173]. 
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Figure 11. RNA interference pathway 
 
In 2001 it was demonstrated that synthetic duplexes mimicking natural siRNAs, could be 
introduced into cultured mammalian cells to elicit sequence-specific inhibition of target 
mRNA, without the induction of interferon response [174, 175]. Additional studies have 
shown that the silencing effect is relatively stable and persist through several cell 
divisions. For these reasons, RNAi is considered a valuable tool for systematic gene 
function analysis, able to bypass the difficulties associated with creating multigene 
knockdown combinations [176]. As example, Sorkina et al,  in order to identify proteins 
that partecipate in chlatrin-mediated endocytosis, have been depleted simultaneously 
thirteen endocytic proteins in HeLa cells, using highly efficient siRNAs [177]. They have 
been demonstrated that the specific and efficient gene silencing by siRNA could be used 
as an approach to functionally analyze the entire cellular machineries, such as the clathrin-
coated pit [178]. 
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In therapeutics, siRNAs hold promise as precise, target-specific silencers of desease-
related genes and human pathogens [179, 180]. Inhibition of anti-angiogenetic or pro-
apoptotic factors in endothelial cells seems to have a great potential for the treatment of 
ischemic diseases, promoting angiogenesis or inhibiting apoptosis [181]. On the other 
side, the advantage of silencing several important angiogenic factors may be in future a 
useful tool for treatment of tumors in which angiogenesis contribute to drug resistance, as 
in hepatocellular carcinoma (HCC) which is dependent on neovascularization. Inhibition 
of factors that are required for angiogenesis should therefore be effective in countering the 
growth of this cancer [182].  Wei et al. have also demonstrated that siRNA-mediated 
knockdown of hTERT (catalytic and rate-limiting subunit of telomerase activity), enhance 
the sensitivity of hepatocellular carcinoma cells to cisplatin, causing much greater extent 
of apoptosis. In this sense, one of the new siRNAs applications could be as “therapeutic 
enhancers” [183]. The enormous therapeutic potential of RNAi-based specific gene 
silencing has prompted enthusiasm for advancement of novel therapies for difficult to treat 
diseases, such as HCC. Developments have been exiting and clinical trials are now in 
progress for treatment. Use of gene silencing to treat HCC faces difficulties, because 
hepatocarcinogenesis is a multistep process with heterogeneous molecular mechanisms 
that drive hepatocyte transformation to malignancy. However, published data are 
promising that desease-specific siRNAs, in combination with advancements in conjugate 
chemistries may soon yield a new of therapeutic reagents. 
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1.6 Aim of the thesis 
Hepatocellular carcinoma (HCC) is one of the most frequent type of liver cancer and is the 
fifth leading cause of cancer-related death worldwide. Although many environmental risk 
factors have been defined, the distinct molecular events that occur during HCC 
development are still not fully understood. Moreover, despite major efforts to improve 
diagnosis and treatment of HCC, available therapeutic options remain very limited in 
efficacy. 
We investigated the oncogenic role of eEF1A1 and eEF1A2 factors in the biology of 
hepatocellular carcinoma, suggesting the possibility that eEF1A forms might become a 
relevant markers related to HCC tumor phenotype. 
The tumorogenic potential of eEF1A1 has been proposed following the observation that its 
over-expression correlates with increased metastatic potential in mammary 
adenocarcinoma [101]. The ectopic expression of eEF1A2 induces the transformation 
towards a malignant phenotype of mouse and rat fibroblast [102] and its expression in a 
human ovarian cell line confers a more aggressive neoplastic phenotype compared to the 
parental cell line [103]. Finally, amplification of the genome region encoding for eEF1A2 
protein has been found in breast, colon and ovary tumors [104-106]. 
Bortezomib is a boronic acid dipeptide derivative and takes part in a new class of anti-
cancer drugs, defined as 26S proteasome inhibitors. In vitro, many tumour cell lines have 
been shown to be susceptible to bortezomib-induced cell cycle arrest or cell death, while 
in vivo phase II and III clinical trial have been conducted in multiple myeloma and non-
Hodgkin’s lymphoma affected patients [149, 168], revealing increased of survival for 
bortezomib-treated patients compared to controls. 
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Despite the broad anti-cancer potential of bortezomib, few informations are available so 
far with regard to its effects on hepatocellular carcinoma (HCC) [88, 93, 184], particularly 
on cell proliferation. It should be noted that in HCC patients, despite alcoholization, 
chemo-embolization or thermal ablation, the local tumor recurrences are the rule and life 
expectancy is short. Thus the identification of novel anti-HCC drugs is of utmost clinical 
relevance. 
In this study, we report the evaluation of the cytotoxic and anti-proliferative effects of 
bortezomib in three human hepatic cell lines with a different phenotype, hepatocyte-like 
for HepG2, low differentiated for HuH7 and undifferentiated for JHH6 [185, 186] based 
on albumin expression, a known marker of hepatic differentiation. 
Our data show that, despite a certain phenotype-dependent effect, bortezomib exerts potent 
cytotoxic and anti-proliferative effects on the three cell lines, supporting the rationale for a 
future use as anti-HCC agent. 
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2.1 EEF1A expression levels 
HepG2 and JHH6 cell lines are here considered models to explore the so far unknown 
biological role of eEF1A in hepatocellular carcinoma. These two cell lines have a 
different morphology, hepatocyte-like for HepG2 and undifferentiated for JHH6 [1, 2]. 
Moreover, albumin mRNA content, a known marker of hepatocyte differentiation, is 
more then 2 times more expressed in HepG2 than in JHH6, further indicating the higher 
differentiation grade of HepG2 compared to JHH6. Thus, the different phenotype allows 
to detect possible correlation between eEF1A and the tumor cell grade. 
 
2.1.1 EEF1A1 and EEF1A2 mRNA levels 
The mRNA levels of EEF1A1 and EEF1A2 were analyzed in sub-confluent (70% 
confluent) HepG2 and JHH6 cells. Total RNA, obtained from normal liver biopsies 
collected during surgical resection for angioma, was used as control (see [3]). EEF1A1 
and EEF1A2 mRNA levels were also evaluated in the HuH7 hepatic cell line [1] which, 
compared to HepG2 and JHH6, displays an intermediate differentiation grade as 
evaluated by morphological inspection and albumin expression.  
A non-quantitative PCR analysis of the amplified genes is reported in Figure 1 while the 
quantitative Real Time PCR data are reported in Figure 2A and 2B. 
Compared to normal liver tissue (Fig. 2A), significant (*p<0.05) 28, 24 and 177 folds 
increase of EEF1A1 mRNA were detected in HepG2, HuH7 and JHH6 cell line, 
respectively. In the case of EEF1A2 (Fig. 2B), a marked increase of the mRNA level 
(205 folds) was observed in JHH6 (*p<0.001), while no significant increment in the 
mRNA levels was found in HepG2 and HuH7. Based on this result, the subsequent 
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experiments were conducted with the two most phenotipically different hepatic cell line, 
HepG2 and JHH6. 
 
 
 
 
 
 
 
 
 
Figure 1. Non-quantitative PCR analysis of EEF1A1, EEF1A2 and 28S genes. DNA-MW=DNA molecular weights (bp). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Real Time PCR of EEF1A1 and EEF1A2. 
 
A) EEF1A1 mRNA levels in HepG2 and JHH6 compared with normal liver. Significant folds increase were detected in HepG2 and 
JHH6 cell lines (*p<0,05). 
B) EEF1A2 mRNA levels in HepG2 and JHH6 compared with normal liver. A marked increase of the mRNA level was observed in 
JHH6 (*p<0,001), while no significant increment in the mRNA levels was found in HepG2. 
The results are expressed as means ±SEM, n=3 
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2.1.2 Gene amplification 
To evaluate the contribution of gene amplification to the increased mRNA levels, 
EEF1A1 and EEF1A2 genes were amplified by 2 specific pairs of primers (see 
Experimental Procedures). As shown in Figure 3A and 3B, a significant (*p<0.05) 
amplification rate of both genes was observed in JHH6 compared to normal liver tissue, 
whereas in HepG2 a significant (*p=0.05) increment was observed for EEF1A2 gene 
only. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Evaluation of genes amplification in HepG2 and JHH6 cell lines compared to normal liver.  
 
Significant gene amplification of EEF1A1 was observed in JHH6 cell line (A) compared with normal liver (*p<0,05), while a 
significant gene amplification of EEF1A2 (B) was observed in both HCC cell lines compared with normal liver. The results are 
expressed as means ±SEM, n=3 
 
 
2.1.3 Western blot analysis 
Western blotting analysis of cytoplasmic and nuclear-enriched eEF1A content was 
performed, in order to distinguish between eEF1A1 and eEF1A2 proteins in absence of 
two specific antibodies available. The data are reported in a representative western blot 
in Figure 4A and summarized as nuclear-enrched versus cytoplasmic ratio in Figure 4B. 
An increased nuclear-enriched/cytoplasmic ratio for eEF1A protein was observed in 
JHH6 compared to HepG2 (p=0.038) (Figure 4A). 
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Figure 4 
 
A) On the top a representative western blotting analysis of 
cytoplasmic and nuclear-enriched eEF1A content in HepG2 
and JHH6 cell lines is reported.  
 
 
B). On the right a summary of nuclear-enriched/cytoplasmic 
ratio. An increased nuclear-enriched/cytoplasmic ratio for 
eEF1A protein was observed in JHH6 compared to HepG2 
(p=0.038). The results are expressed as means ±SEM, n=3 
 
 
 
2.1.4 Apopotsis 
The capacity of eEF1A1 and eEF1A2 to modulate programmed cell death in relation to 
the expression levels [4], prompted us to evaluate the apoptotic rate of HepG2 and JHH6 
cell lines. In sub-confluent cells (two days after cell plating in complete medium) no 
differences were detected among HepG2 and JHH6 in the apoptosis rate evaluated by 
the percent of Annexin V positive cells (see [3]). 
The Annexin V test (Fig. 5) is based on the observation that soon after initiating 
apoptosis, cells translocate the membrane phosphatidylserine (PS) from the inner face of 
the plasma membrane to the external face. Once on the cell surface, phosphatidylserine 
can be easily detected by staining with a fluorescent conjugate of Annexin V, a protein 
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that has an high affinity for PS. By conjugating fluorescein isothiocyanate (FITC) to 
Annexin V, it is possible to identify and quantitate apoptotic cells on a single-cell basis 
by flow cytometry. Staining cells simultaneously with FITC-Annexin V (green 
fluorescence) and the non-vital dye propidium iodide (red fluorescence) allows the 
discrimination of intact cells (FITC-/PI-), early apoptotic (FITC+/PI-), late 
apoptotic/necrotic cells (FITC+/PI+) and cell debris (PI+). 
 
 
Figure 5. The Annexin V test. 
Phosphatidylserine can be easily detected by staining with a 
fluorescent conjugate of Annexin V, a protein with an high 
affinity for PS. Annexin V conjugated with fluorescein 
isothiocyanate (FITC) can identify apoptotic cells on a single-
cell basis by flow cytometry. Staining cells with FITC-Annexin 
V (green fluorescence) and the non-vital dye propidium iodide 
(red fluorescence) allows the discrimination of living cells, early 
apoptotic, late apoptotic/necrotic cells and cell debris. 
 
 
 
Since the influence of eEF1A on apoptosis induced by serum deprivation has been 
reported [5-7], we explored the effects of serum removal on the apoptotic rate. No 
difference was observed between JHH6 and HepG2 after 2 days of starvation in spite of 
a general increase in Annexin V positive cells as compared to non starved cells. To 
evaluate the effect of one additional pro-apoptic condition, cells were treated by the 
known apoptic inducer staurosporin [8, 9]. Once again, no major differences were noted 
in the amount of apoptotic cells. Notably, in Hela cells, used as control, the amount of 
Annexin V positive cells, i.e. apoptotic cells, did not substantially change under all the 
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condition tested. As expected, the percent of Annexin V positive cells was inversely 
related to the number of cells in both HepG2 and JHH6 cell line (see [3]). 
 
2.1.5 Proliferation 
Due to the implication of eEF1A in cell proliferation [6, 10-12], the relation between 
EEF1A expression-level/subcellular-localization and the proliferative activity was 
investigated by measuring the amount of different cell cycle inhibitors (p16ink4a, 
p21waf/cip1 and p27kip1), and mediators of the cell cycle such as cyclins (cyclin E1, cyclin 
D1, cyclin A). The amount of the transcription factor E2F1 and of the newly synthesized 
DNA were also investigated. In sub-confluent cells, p16ink4a and p27kip1, but not 
p21waf/cip1, are more elevated in HepG2 compared to JHH6 (Fig. 6). On the contrary, no 
significant difference was observed for the protein levels of cyclin E1, cyclin D1, cyclin 
A and of the transcription factor E2F1 (see [3]). 
In HuH7 cell line (a low differentiated HCC cell line), Maeta et Al. [13] have 
demonstrated that p16ink4a gene promoter is methylated. They also observed that the 
demethylating agent, 5-aza-2-deoxycytidine (5-Aza-CdR), up-regulated p16ink4a mRNA, 
increasing p16 protein expression. It clearly decreased the phosphorylation levels of 
pRb, resulting in a consequent inhibition of HuH7 cells growth. 
For this reason it was not possible to detect p16ink4a in HuH7 but also in JHH6 cell line 
(undifferentiated HCC cell line). A representative western blot of p16ink4a in HepG2, 
HuH7 and JHH6 cell lines is reported in Figure 7. 
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Figure 6. Cell cycle inhibitors.  
 
The relation between EEF1A expression-level/subcellular-localization and  the 
proliferative activity was investigated by measuring the amount of different cell 
cycle inhibitors (p16ink4a, p21waf1/cip1 and p27kip1), and mediators of the cell cycle. In 
sub-confluent cells, p16ink4a and p27kip1, but not p21waf1/cip1, are more elevated in 
HepG2 compared to JHH6. A representative western blot was reported. 
 
 
 
 
 
 
 
 
Figure 7. p16ink4a cell cycle inhibitor detection in HCC 
cell lines. 
Detection of p16ink4a in HepG2, HuH7 and JHH6. A 
representative western blot is reported.  
 
 
 
 
 
No variation was observed in the proliferative activity as evaluated by bromodeoxyuridine 
(BrdU) incorporation in HepG2 and JHH6, as reported in Figure 8. 
 
 
 
 
 
 
 
 
Figure 8.Proliferation assay evaluated by BrdU incorporation. 
Regarding to HepG2 and JHH6 cell lines, no variations were 
observed. 
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2.1.6 Senescence assay 
However, between two and four days after reaching cell confluence, HepG2 
(differentiated HCC) exit from the cell cycle more massively than HuH7 (low 
differentiated HCC) and JHH6 (undifferentiated HCC) cell lines as indicated by the 
evident staining for the β-gal associated senescence test (see Experimental Procedures) 
[14]. Data are reported in Figure 9. 
 
 
Figure 9. β-gal associated senescence test. 
 
Reported are representative imagines of confluent HepG2, HuH7 and JHH6 cells stained for senescence-associated β-galactosidase 
and analyzed by microscopy at a 20x magnification. 
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HuH7 seem to have a similar behaviour like JHH6 at two days after confluence, while at 
four days JHH6 grow and are not affected by senescence stain like other cell lines. Hela 
cells did not significantly stain for the senescence associated β-gal test (see [3]). 
 
 
2.2 Inhibition of 26S proteasome in HCC cell lines by bortezomib 
We monitored the effects of bortezomib on HepG2, HuH7 and JHH6, an in vitro model 
of hepatocellular carcinoma. The bortezomib concentrations used were chosen to stay 
well below the maximal amount/cm2 recommended for in vivo application [15]. 
Moreover, two days incubation were found to be optimal to study bortezomib effects. 
 
2.2.1 Bortezomib inhibits the 26S proteasome 
The first step was first to evaluate that bortezomib inhibits the chymotrypsin – like 
activity of 26S proteasome in HCC cell lines considered, because there are no data 
published at regarding. The protocol used was adapted to HCC cell lines from 
Reinheckel T et Al. and Powell SR et Al. [16, 17] 
Determination of 26S proteasome activity with fluorogenic substrates requires ATP, in 
order to asses function of the 19S-regulatory particle. Chymotrypsin-like activity was 
monitored using fluorogenic substrate Suc-LLVY-Amc. Collected cells were suspended 
in Lysis Buffer (see Experimental Procedures) and immediately disrupted by three 
freezing/thawing steps through liquid nitrogen, monitoring the cell vitality using trypan 
blue. 60 µg of protein solution (evaluated by BCA protein staining) was adjusted with 
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ATP and Suc-LLVY-Amc 26S proteasome substrate, and incubated at 37°C for 45 
minutes. 
 
 
 
 
 
 
Figure 10. Fluorigenic 26S proteasome Suc-LLVY-Amc substrate reaction. 
 
The reaction was quenched using ice-cold ethanol. Evaluation of chymotrypsin-like 
activity function of 26S proteasome was conducted analysing fluorescent signal 
produced by free 7-amino-4-methylcoumarine present in solution, only if 26S 
proteasome degraded the substrate (Fig. 10). As reported in Figure 11, a dose dependent 
in 26S proteasome substrate degradation was evident in bortezomib-treated cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. 26S proteasome chymotryptic-like activity inhibition.  
Suc-LLVY-Amc substrate decreased of degradation was evident in bortezomib-treated cells compared to controls, confirming the 
inhibition of the chymotripsyn-like activity of 26S proteasome in all HCC cell lines. The results are expressed as means ±SEM, n=6 
(§p<1x10-5, #p<2x10-5, *p<1x10-5, compared to NT)  
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compared to controls, comparing the fluorescence value of the maximal activity (non-
treated cells control) with the fluorescent values of bortezomib-treated cells confirming 
the inhibition of the chymotripsyn-like activity of 26S proteasome (§p<1x10-5 for 
HepG2, *p<1x10-5 JHH6, #p<2x10-5 for HuH7, compared to NT). A comparable 
reduction of 26S proteasome substrate degradation was observed in HepG2 and JHH6 
cell lines, while HuH7 were more affected by bortezomib, as evidenced by major 
decrease of chymotrypsin-like activity. 
 
2.2.2 Effects of bortezomib on cells viability 
The incubation of increasing amounts of bortezomib with HepG2, HuH7 and JHH6 
resulted in a significant decrease in the number of hepatic cells as evidenced by cell 
counting (Fig 12) and microscopic inspection (Fig. 13A, 13B and 13C). Notably, in 
HepG2 and HuH7 the reduction was already evident at 20 nM of bortezomib (*p<0.016, 
#p<0,0002 respectively), while in JHH6 a significant reduction was evident only at 40 
nM (§p<0.05), suggesting a different drug sensitivity.  
 
 
 
 
 
 
 
 
 
 
Figure 12. Cell counting. 
The reduction of HepG2 and HuH7 cell lines was evident at 20 nM of bortezomib (*p<0.016, #p<0,0002 respectively, compared to 
NT). A significant reduction of JHH6 was evident only at 40 nM (§p<0.05, compared to NT), while at 80 nM of bortezomib all cell 
lines were high affected. The results are expressed as means ±SEM, n=4. 
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An increase of HepG2 and JHH6 floating cells was visible at 80 nM of bortezomib (Fig. 
12-III), nevertheless for the HuH7 cell line, the decrease was so high that it was not 
technically possible to detect living cells, as evidenced in Figure 13B-III. 
HepG2 cell line grows in colonies as shown in Figure 13-A-I, as a result of a 
differentiated phenotype. We evaluated in this HCC cell line the possible effects of 
bortezomib analysing colonies area and colonies number at low microscopical 
inspection. 
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Figure 13. Microscopical inspection of HepG2, HuH7 and JHH6 at two different magnifications.  
For each panel: top row=5x magnification, bottom row=20x magnification, I=Non-treated cells, II=40 nM of bortezomib, III=80 nM 
of bortezomib. 
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Results indicated a reduction of colonies area (§p<0.02), suggesting a cytostatic effect, 
and a reduction of the number of colonies (*p<0.05), supporting a cytotoxic effect, 
compared to NT (Fig. 14). 
 
 
Figure 14. Evaluation of 
colonies area and 
number in HepG2 cell 
line. 
On the left results about 
colonies area evaluation, 
while on the right 
colonies number 
detection. §p<0.02, 
*p<0.05, compared to 
NT. The results are 
expressed as means 
±SEM, n=5.   
 
In order to evaluate whether bortezomib exerts a cytostatic or a cytotoxic effect, a cell 
death or cytotoxicity test was evaluated by lactate dehydrogenase enzyme test. 
 
2.2.3 Bortezomib exerts a cytotoxic effect 
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme which is present in 
cytosol of all cell types, and it is released into the cell culture supernatant upon damage 
of the cytoplasmic membrane. The test utilizes a coupled enzymatic reaction in which 
LDH oxidizes lactate to pyruvate, which then reacts with tetrazolium salt to form 
formazan. The increase in the amount of formazan produced in culture supernatant 
directly correlates to the increase in the number of lysed cells. The formazan-dye is 
water-soluble and can be detected spectrophotometrically at 500 nm.  
For all HCC cell lines, we observed a dose-dependent increase in LDH enzyme in cell 
supernatant (Fig. 15). At concentration of 80 nM of bortezomib the rise in LDH amount 
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in HuH7 and JHH6 were more contained than in HepG2 (*p<0.014, #p<8x10-5, §p<0.03, 
compared to NT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. LDH cytotoxicity test. 
For all HCC cell lines, we observed a dose-dependent increase in LDH enzyme in cell supernatant. At concentration of 80 nM of 
bortezomib the rise in LDH amount in HuH7 and JHH6 were more contained than in HepG2. The results are expressed as means 
±SEM, n=6 (*p<0.014, #p<8x10-5, §p<0.03, compared to NT). 
 
We performed also the LDH test at 12 and 24 hours (Fig. 16) after bortezomib 
treatments in HepG2 and JHH6 cell lines (not for HuH7). Data indicated not only a 
dose-dependent cytotoxic effect of bortezomib (Fig. 15), but also a time-dependent 
increase of the enzyme amount in cells medium (Fig. 16). For HepG2, the cytotoxic 
effect was evident just at 12 hours (40 nM of bortezomib, §p<0.015), while at 24 hours 
the LDH enzyme amount approximately reached the level (§§p<2.8x10-5) observed at 2 
days of incubation (40 nM of bortezomib) and reported in Figure 15. 
Regarding to JHH6, the undifferentiated HCC cell line, it confirmed to be less sensitive 
to bortezomib treatments compared to HepG2. At 12 hours JHH6 were affected few by 
treatments (40 nM of bortezomib, *p<0,02), while at 24 hours after bortezomib 
administration, the LDH enzyme amount observed (**p<0.007) was very similar with 
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HepG2 LDH enzyme amount detected at 12 hours (Fig. 16). At 20 nM of bortezomib 
JHH6 were not affected both at 12 and 24 hours after treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Time-dependent LDH cytotoxicity test. 
For HepG2, the cytotoxic effect was evident just at 12 hours (40 nM of bortezomib, §p<0.015), while at 24 hours the LDH enzyme 
amount approximately reached the level (§§p<2.8x10-5) observed at 2 days of incubation (40 nM of bortezomib) and reported in 
Figure 15. Regarding to JHH6, the undifferentiated HCC cell line, it confirmed to be less sensitive to bortezomib treatments 
compared to HepG2. At 12 hours JHH6 were affected few by treatments (40 nM of bortezomib, *p<0,02), while at 24 hours after 
bortezomib administration, the LDH enzyme amount observed (**p<0.007) was very similar with HepG2 LDH enzyme amount 
detected at 12 hours. At 20 nM of bortezomib JHH6 were not affected both at 12 and 24 hours after treatment. The results are 
expressed as means ±SEM, n=6. 
 
Cytotoxicity LDH enzyme test was confirmed through cell debris evaluation by flow 
cytometry, after cell staining by propidium iodide. Propidium iodide (PI) binds to DNA 
by intercalating between the basis with little or no sequence preference and with a ratio 
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of one dye per 4/5 base pair of DNA. PI also binds RNA, so cell debris evaluation 
requires RNAse treatment in order to distinguish PI-DNA staining from PI-RNA (see 
Experimental Procedures). Once the dye is bound to nucleic acids, its fluorescence is 
enhanced 20- to 30-folds. PI is membrane impermeant and generally excluded from 
viable cells, so it could be used for identifying dead cells, which have pearced 
membranes. For this reason PI staining is an alternative cytotoxicity test and we used it 
to confirm LDH enzyme test. 
We observed an increase of cell debris increasing bortezomib concentrations in all HCC 
cell lines (Fig. 17). Notably, at the concentrations of 40 and 80 nM of bortezomib, in 
JHH6 the rise in cell debris amounts were more contained than in HepG2 and HuH7 
(#p<0.003, *p<0.033, §p<0.0001, compared to NT). At 80 nM of bortezomib it was not 
technically possible to evaluate HuH7 cell debris.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Cell debris evaluation in HCC cell lines. 
An increase of cell debris increasing bortezomib concentrations was observed. At the concentrations of 40 and 80 nM of bortezomib, 
in JHH6 the rise in cell debris amounts were more contained than in HepG2 and HuH7. The results are expressed as means ±SEM, 
n=4 (#p<0.003, *p<0.033, §p<0.0001, compared to NT). At 80 nM of bortezomib it was not technically possible to evaluate HuH7 
cell debris. 
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2.2.4 Bortezomib reduces cell viability 
Cell viability was investigated in order to evaluate whether bortezomib exerts a dose-
dependent effect as supposed above, using an MTT assay. The MTT assay is a test for 
measuring cell vitality by mithocondrial activity. Yellow (3-(4,5-dimethylthyazol-2-yl)-
2,5-diphenyltetrazolium) bromide (MTT) is reduced to purple formazan by a 
mithocondrial reductase. The amount of purple formazan is indicative of the vitality of 
the cells. The formazan is dissolved in dimethylsulphoxide (DMSO) afterwards and then 
quantified by measuring the absorption at 590 nm (see Experimental Procedures). MTT 
test was performed two days after bortezomib administration (Fig. 18). A dose-
dependent reduction in the amount of viable cells was observed (§p<0.023, #p<2x10-9 
and *p<0.01 for HepG2, HuH7 and JHH6 respectively, starting from 20 nM bortezomib, 
compared to NT).  
 
 
Figure 18. MTT test performed two days after bortezomib administration.  
A dose-dependent reduction in the amount of viable cells was observed. The results are expressed as means ±SEM, n=7 (§p< 0.023, 
#p<2x10-9 and *p<0.01 for HepG2, HuH7 and JHH6 respectively, starting from 20 nM bortezomib, compared to NT). JHH6 resulted 
to be less affected than HepG2 and HuH7 by bortezomib, particularly at concentration higher than 20 nM. 
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JHH6 resulted once again to be less affected than HepG2 and HuH7 by bortezomib, 
particularly at concentration higher than 20 nM. This experiment confirms the dose-
dependent effect exerts by bortezomib. 
 
Prolonging bortezomib incubation up to six days (Fig. 19), a similar behaviour was 
observed, but in the context of a more pronounced reduction in cell viability compared 
to the two days incubation. At six days, in HepG2 and HuH7 at 10 nM of bortezomib 
(§p<1.8x10-15, #p<1x10-15 respectively, compared to NT) we observed similar results 
found at 320 nM of bortezomib at two days of incubation (Fig. 18). At concentrations 
higher than 10 nM nor HepG2 nor HuH7 viable cells were detected. JHH6 vability 
decreased significantly at 20 nM of bortezomib (*p<2.5x10-5, compared to NT). At 160 
nM
A similar behaviour was observed, but in the context of a more pr
 of bortezomib no viable cells were detected (Fig. 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. MTT test performed six days after bortezomib administration.  
onounced reduction in cell viability compared to the two days of 
incubation. Regarding to HepG2 and HuH7, at 10 nM of bortezomib (§p<1.8x10-15, #p<1x10-15 respectively, compared to NT) we 
observed similar results found at 320 nM of bortezomib at two days of incubation, while for JHH6 a significant reduction of viable 
cells were observed at 20 nM of bortezomib (*p<2.5x10-5, compared to NT). The results are expressed as means ±SEM, n=7. 
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2.2.5 Effects of bortezomib on apoptosis activation 
Apoptosis activation was evaluated by the Annexin V test as described above (see 
Experimental Procedures). Typical dot-plots related to apoptotic evaluation in HepG2, 
HuH7 and JHH6 cell lines are reported in Figure 20. Dot-plot is divided into four 
quadrants: Q3 (proliferating cells), Q4 (early apoptotic cells), Q2 (late apoptotic cells) 
and Q1 (cell debris). Apoptosis value is derived from Q2 + Q4 values sum. 
In HepG2 a pro-apoptotic effect was detected at 20 nM of bortezomib, whereas at upper 
nt of cell debris were predominant. 
like in HepG2, but modest if compared with citotoxicity evidenced by increasing of cell 
debris (at 80 nM of bortezomib Q1=25,9%, Q1+Q4=4,8%, data not shown). In HuH7 we 
 by bortezomib treatment at 20 nM, 
on the contrary at 40 nM a decreased of apoptotic cells compared to control, were 
observed. 
after bortezomib treatments, in order to exclude an earlier increase of apoptotic cells. 
 bortezomib 
treatments. However, we cannot exclude that the reduction in the cell number and 
viability reported (Fig. 12 an 18) could also depend on the pro-apoptotic effect induced 
by bortezomib, observed at two days after treatments. 
 
concentrations (40 nM shown only) the amou
Regarding to JHH6 cell line, bortezomib exerts a major pro-apoptotic effect at 40 nM 
have not observed any pro-apoptotic effect mediated
Annexin V test was also performed monitoring the HepG2 and JHH6 cell lines 24 hours 
Reported dot-plots (Fig. 21) evidenced no pro-apoptotic effect induced by
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Figure 20. Dot-plots related to apoptotic evaluation at 2 days after treatments. 
Q3=proliferating cells, Q4=early apoptotic cells, Q2=late apoptotic cells, Q1=cell debris, Q2+Q4=apoptotic cells 
 HepG2 a pro-apoptotic effect was detected at 20 nM of bortezomib, whereas 40 nM the amount of cell debris were predominant.
Regarding to JHH6 cell line, bortezomib exerts a major pro-apoptotic effect at 40 nM like in HepG2, but modest if compared with
citotoxicity evidenced by increasing of cell debris (at 80 nM of bortezomib Q1=25,9%, Q1+Q4=4,8%, data not shown). In HuH7 we 
have not observed any pro-apoptotic effect mediated by bortezomib treatment at 20 nM, on the contrary at 40 nM a decreased o
apoptotic cells compared to control, were observed. Dot-plots report fluorescent signal from Annexin V FITC on x-axis and PI 
detection on y-axis.  
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Figure 21. Dot-plots related to apoptotic evaluation at 24 hours after treatments. 
Q3=proliferating cells, Q4=early apoptotic cells, Q2=late apoptotic cells, Q1=cell debris, Q2+Q4=apoptotic cells 
Reported dot-plots evidenced no pro-apoptotic effect induced by bortezomib treatments for HepG2 and JHH6 cell lines. Dot-plots
port fluorescent signal from Annexin V FITC on x-axis and PI detection on y-axis. 
2.2.5.1 Western blot of Bax/Bcl-2 and PARP proteins 
In order to evaluate apoptosis data observed by flow citometry, we considered some
arkers related to intrinsic apoptosis pathway. We investigated the protein levels of 
 
 
 
 
 
 
 
 
 
 
re
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
m
) cleavage [18-20]. 
apoptosis. Internal damages to the cell causes the activation of protein Bax, which 
ibits the protective effect of Bcl-
2, inserts itself into the outer mitochondrial membrane punching holes in it and causing 
Bax/Bcl-2 and poly-(ADP)-ribose-polymerase (PARP
In a healty cell, the outer mitochondria membrane display the protein Bcl-2, that inhibits 
migrates to the surface of the mitochondria where it inh
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the cytochrome c to leak out. The release of cytochrome c binds to the protein Apaf-1 
(Apoptosis Protein Activating Factor-1), forming complexes called apoptosomes, that 
activate caspase-9 [21, 22].  
The caspases are a family of proteins that are one of the main executors of the apoptotic 
process. They belong to a group of enzymes known as cysteine proteases and exist 
within the cell as inactive pro-forms or zymogens. These zymogens can be cleaved to 
form active enzymes following the induction of apoptosis. One of the hallmarks of 
apoptosis is the cleavage of chromosomal DNA into nucleosomal units. The caspases 
play an important role in this process by activating DNases, inhibiting DNA repair 
enzymes and breaking down structural proteins in the nucleus.  
 cell  to lysis and death 
compared to control). In JHH6 cell line, bortezomib treatments increased Bax protein 
PARP is an highly conserved chromatin-associated protein which has the capacity to 
polymerize ADP-ribose (PAR) from nicotinamide adenine dinucleotide (NAD+). In 
response to DNA damage caused by environmental genotoxic agents and endogenous 
cellular reactions, PARP binds rapidly to single-strand DNA nicks and catalyzes the 
transfer of ADP-ribose from its substrate NAD+ to a number of nuclear acceptors, in 
order to assisting in the DNA repair. This ability of PARP to repair DNA damage is 
prevented following cleavage of  PARP by caspase-3, leading
[23, 24].  
A representative western blot reported in Figure 22 confirmed the Annexin V test by 
flow cytometry (Fig. 20). In HepG2 at 20 nM of bortezomib we observed a decrease of 
anti-apoptotic protein Bcl-2 (not detectable in treatments) and pro-apoptotic protein Bax. 
The ratio Bax/Bcl-2 in treatments is in favour of the pro-apoptotic effect exerted by Bax 
itself, and this fact is supported by an increase of the cleaved PARP fragment (1.8 folds 
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levels (1.29 folds at 20 nM /1.36 folds at 40 nM, compared to control), while Bcl-2 
levels wer
stern blot of apoptosis regulators 
esentative western blot reporting Bax/Bcl-2 and PARP levels. In HepG2, at 20 nM of bortezomi
e not affected like HepG2 cell line. The ratio Bax/Bcl-2 increase in treatments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. We
This is a repr b we observed a 
fragment (1.8 folds compared to control). In JHH6 cell line, bortezomib treatments increased Bax protein levels (1.29 folds at 20 nM 
PARP protein is detected at 116 kDa, while the fragment cleavaged by caspase-3 at 85 kDa, as reported.  
 
2.2.6 Effects of bortezomib on cell cycle phases distribution 
 the chymotrypsin-
like activity of 26S proteasome (Fig. 11), which resulted in a potent anti-proliferative 
effect, as evidenced by the decreased of cells number (Fig. 12) and cell viability (Fig. 
(1.32 folds at 20 nM and 1.65 folds at 40 nM of bortezomib, compared to control)  
Nevertheless, PARP cleavage was confirmed at 40 M of bortezomib only (4.15 folds 
compared to control), as observed through flow cytometry (Fig. 20). 
 
decrease of anti-apoptotic protein Bcl-2 (not detectable in treatments) and pro-apoptotic protein Bax. The ratio Bax/Bcl-2 in 
treatments is in favour of the pro-apoptotic effect exerted by Bax itself, and this fact is supported by an increase of the cleaved PARP 
/1.36 folds at 40 nM, compared to control), while Bcl-2 levels were not affected like HepG2 cell line. Nevertheless, PARP cleavage 
was confirmed at 40 M of bortezomib only (4.15 folds compared to control), as observed through flow cytometry (Fig. 20). 
We observed in HCC cell lines considered that bortezomib inhibits
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18). This fact is reasonably related with the citotoxic effect induced by bortezomib (Fig. 
15 and 17), and with a modest apoptosis induction observed (Fig. 20 and 22). 
We investigated the effects of bortezomib to cell cycle, using a classical method for the 
analysis of cell cycle distribution by flow cytometric measurement of DNA content 
using bromodeoxyuridine (BrdU) and propidium iodide (PI) (see Experimental 
Procedures). 
BrdU is an analog of the DNA precursor thymidine and it is incorporated into newly 
ith PI 
binds total DNA and with this combination, two-color flow cytometric analysis permits 
 sinthesizing DNA (BrdU 
incorporation), in terms of their cell cycle position (G1/G0, S and G2/M by PI staining 
intensities). Green fluorescence from the fluorescein-conjugated antibody is a measure 
of BrdU incorporation, while red fluorescence from the PI is a measure of DNA. A 
representative cell cycle dot-plots are reported in Figure 23.  
aluation in 
HepG2, HuH7 and JHH6 respectively. 
 
 
synthesized DNA by cells entering and progressing through the S phase of the cell cycle. 
The incorporated BrdU is stained with a specific anti-BrdU fluorescent antibody. The 
levels of cells-associated BrdU are then measured by flow cytometry. Staining w
the enumeration and characterization of cells that are actively
Figures 24, 25 and 26 summarize the entire data about cell cycle phases ev
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re 24. Summary of cell cycle phases evaluation in HepG2. 
0 and 40 nM of bortezomib a marked reduction in the amount of S phase cells (§p<6x10-8) and an increase of G2/M (§§p<6x
phase cells were observed, compared to NT. The results are expressed as means ±SEM, n=6. 
 
 
 
 
 
 
 
 
 
igure 23. Representative dot-plot of  bortezomib effects to cell cycle, limiting to NT and 40 nM of bortezomib. 
ot-plots report PI detection on x-axis and BrdU incorporation on y-axis (Q3=G1/G0 phase cells,  Q1=S phase cells, Q2+Q4= G2/M 
phase cells) 
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I
JHH6 (Fig. 26), a similar effect observed for HepG2 was plain only at 40 nM
b (*p<7x10-4 and **p<1x10-4 for S and G2/M phase cells, respectively, 
ared to NT). No major variations in the amount of G1 and G0
detected for HepG2 and JHH6. For all HCC cell lines, the decrease of
2/M phase cells trends were confirmed also at 80 nM bortezom
shown). At higher bortezomib concentrations, the cytotoxic effect was preponderant 
over the anti-proliferative effect and no cell cycle analysis was technically
n HepG2 (Fig. 24), both at 20 and 40 nM of bortezomib a marked reduction in the 
mount of S phase cells (§p<6x10-8) and an increase of G2/M (§§p<6x10-4) phase cells 
ere observed, compared to NT. HuH7 (Fig. 25) evidenced a significant increase of 
G1/G0 (#p<0.01) at 20 nM of bortezomib. Regarding to S (##p<0.01) phase cells, in 
HuH7 was detected a similar reduction like in HepG2 at 20 and 40 nM of bortezomib, 
while the increase of  G2/M (###p<0.014) was evident only at 40 nM of bortezomib. In 
 of 
bortezomi
comp  phase cells were 
 S phase cells and 
increase of G ib (data not 
 possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Summary of cell cycle phases evaluation in HuH7. 
at 20 and 40 nM of bortezomib, while the increase of  G2/M (###p<0.014) was observed only at 40 nM of bortezomib, compared to 
 
a
w
 
HuH7 evidenced a significant increase of G1/G0 (#p<0.01) at 20 nM of bortezomib, a marked reduction of S (##p<0.01) phase cells 
NT. The results are expressed as means ±SEM, n=6. 
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 of cell cycle phases evaluation in JHH6. 
effect observed for HepG2 was observed only at 40 nM of bortezomib (*p<7x10-4 and **p<1
tively, compared to NT). The results are expressed as means ±SEM, n=6. 
2.2.6.1 Effects of bortezomib on the protein and mRNA levels of cell cycle regula
ree HCC cell lines considered, flow cytometry experime
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Summary
In JHH6 a similar x10-4 for S and G2/M 
phase cells, respec
 
tors
 
 
 
 
 
In the th nts revealed that 
ease of S phase cells and an increase of G2/M 
G1/G0 phase cells (only at 20 nM of bortezomib, Fig. 25). In order to understand these 
results, we evaluated the levels of the major cell cycle factors by western blot (Fig. 27A, 
28A and 29A) and Real Ti
considered, a rep s, is reported (Fig. 
27A, 28A a
eir transcription 
regulator E2  of pRB were considerably 
bortezomib treatments cause an high decr
phase cells (Fig. 23, 24, 25 and 26). Regarding to HuH7 it was detected an increase of 
me PCR (Fig. 27B, 28B and 29B). For each cell cycle protein 
resentative blot, out of three independent experiment
nd 29A).  
In HepG2, the protein levels of cyclin D1, cyclin A2, CdK2, of th
F1 and of the hyper-phosphorylated form
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decreased compared to control cells (Fig. 27A). The mRNA quantification revealed in 
HepG2 a significant decrease (p<3x10-8) of cyclin D1 (§p<3x10-8), E2F1 (§§p<8x10-7), 
CdK2 and cyclin A2 (p<8x10-5) mRNAs, consistent with the protein data (Fig. 27A) 
observed. No variation was observed for cyclin E1 mRNA (Fig. 27B). Moreover, a 
 p21  together with a 
more contained (**p<1x10-5) increase of p27kip1 mRNA (Fig. 27B). A somewhat 
 
 
 
 
 
 
 
 
 
 
 
Figure 27A. A representative western blot of cell cycle regulators in HepG2 cell line.  
 
 
 
 
 
 
 
significant (*p<3x10-9) and marked increase was observed for waf1/cip1
decrease in p53 levels were also observed (**p<1x10-5). 
PP-pRB=hyperphosphorylated pRB, P-pRB= hypophosphotylated pRB. 
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igure 27B. mRNA levels of the cell cycle regulators in HepG2 cell line. 
B 1x10-5). Up-regulation was observed for TP53 
(* K2 (@p<7.4x10-5), compared to NT. No variation was 
observed for mRNA levels of CCNE1. Statistical analysis refers to 40 nM of bortezomib. CDKN1A=p21waf1/cip1, CDKN1B=p27kip1, 
P53=p53, CCND1= cyclin D1, CCNE1= cyclin E1, CCNA2= cyclin A2. The results are expressed as means ±SEM, n=6. 
 
In HuH7 a cosiderably decrease of the hyper-phosphorylated form of pRB, of E2F1 
ranscriptional factor and cyclin A2, together with a slight decrease of CdK2 was detected 
Fig. 28A). As observed in HepG2, the levels of cyclin E1 were substantially not affected, 
as reported in western blot (1.29 folds for 40 nM of bortezomib, compared to control cells, 
Fig. 28A) and m
ere slightl itors it 
as found o
eal Time se of  
21waf1/cip1
2 (§§p<8x
 
 
 
 
 
 
 
F
ortezomib up-regulates the mRNA levels of CDKN1A (*p<3x10-9) and CDKN1B (**p<
*p<1x10-5), CCND1 (§p<3x10-8), E2F1 (§§p<8x10-7), CCNA2 and CD
T
 
t
(
RNA detection by Real Time PCR (Fig. 28B). Cyclin D1 protein levels 
y decreased only at 40 nM of bortezomib. Regarding to cell cycle inhib
nly a considerable increase of p21waf1/cip1 (Fig. 28A).  
 PCR confirmed the data observed by western blot analysis: an increa
 (*p<5x10-5), cyclin D1 (**p<0.015), and a decrease of E2F1 (§p<0.001), cyclin 
10-8) and CdK2 (#p<0.0001) mRNAs, compared to NT (Fig. 28B). 
w
w
R
p
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Figure 28A. A representative western blot of cell cycle regulators in HuH7 cell line.  
 
 
 
 
 
igure 28B. mRNA
ortezomib admins  Down-regulation was 
bserved for E2F1 ( ved for mRNA 
vels of  TP53=p53, CCND1= 
cyclin D1, CCNE1
 
 
 
 
 
 
 
 
 
 
PP-pRB=hyperphosphorylated pRB, P-pRB= hypophosphotylated pRB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
F  levels of the cell cycle regulators in HuH7 cell line. 
tration up-regulates the mRNA levels of CDKN1A (*p<5x10-5) and cyclin D1 (**p<0.015).
§p<0.001), CCNA2 (§§p<8x10-8) and CDK2 (#p<0.0001), compared to NT. No variation was obser
 CCNE1. Statistical analysis refers to 40 nM of bortezomib. CDKN1A=p21waf1/cip1, CDKN1B=p27kip1,
= cyclin E1, CCNA2= cyclin A2. The results are expressed as means ±SEM, n=6. 
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In JHH6, a reduction in the protein levels of cyclin A2, of the transcription factor E2F1 
and of the hyper-phosphorylated form on pRB were observed compared to control cells 
(Fig. 28A). In JHH6, as observed in HepG2 and HuH7, the levels of cyclin E1 were 
substantially not affected, as reported in western blot (Fig. 29A) and mRNA detection by 
Real Time PCR (Fig. 29B). Additionally, protein levels of the other cell cycle regulators 
were substantially unaffected, except for p21waf1/cip1, that evidenced a slight increase. 
 
kip1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29A. A representative western blot of cell cycle regulators in JHH6 cell line.  
PP-pRB=hyperphosphorylated pRB, P-pRB= hypophosphotylated pRB. 
Regarding to mRNA levels, except for the increase of cyclin D1 (*p<0.008 at 40 nM of 
bortezomib, compared to NT), observed also in HuH7, and the tendency towards the 
decrease of cyclin A2, E2F1 and p27  mRNAs, no major variations were observed for 
the other mRNAs considered (Fig. 28B), confirming protein levels data.  
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A levels of the cell cycle regulators in JHH6 cell line. 
 
 
Figure 29B. mRN
In JHH6, except for the increase of cyclin D1 (*p<0.008 at 40 nM of bortezomib, compared to NT) and the tendency towards the 
kip1 d for the other mRNAs considered, confirming 
yclin D1, CCNE1= cyclin E1, CCNA2= cyclin 
 
ggests that the 
variations in the expression levels of the E2F1 target genes observed following 
bortezomib treatment depends on E2F1 down-regulation. 
 
2.2.6.2 Protein levels o
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
decrease of cyclin A2, E2F1 and p27  mRNAs, no major variations were observe
protein levels data. CDKN1A=p21waf1/cip1, CDKN1B=p27kip1, TP53=p53, CCND1= c
A2. The results are expressed as means ±SEM, n=6. 
Notably, both in HepG2 and JHH6, the depletion of E2F1 by an E2F1 directed siRNA 
(siE2F1), resulted in variation in the protein levels of the E2F1 regulated genes (cyclin 
D1, cyclin E1, cyclin A2, CdK2) and of the phosphorylation status of pRB not dissimilar 
to those observed following bortezomib treatment [Baiz et al]. This su
f P-cyclin E1 (T395) 
The protein levels of cyclin E1, were slight increased in HepG2 and HuH7 (1.7 and 1.29 
ared to control cells, Fig. 27A and 27B). This fact neither depends on an 
mount detected by Real Time PCR (Fig. 27B and 28B) nor on a 
folds, comp
increased mRNA a
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reduced phosphorylation of cyclin E1 residue T395 (Fig. 30), a site whose 
phosphorylation is known to drive cyclin E1 degradation via proteasome [25]. 
 
 
 
 
 
 
 
 
 
 
 
Cyclin E1 levels were sight increased in HepG2 and HuH7 (1.7 and 1.29 folds, compared to control cells). This fact neither depends 
on an increased mRNA amount detected by Real Time PCR (Fig. 27B and 28B) nor on a reduced phosphorylation of cyclin E1 
 
2.2.6.3 Relation between cyclin E1, E2F1 and LRH1
 
Figure 30. Western blot of Cyclin E1 phosphorylated at T395. 
residue T395, a site whose phosphorylation is known to drive cyclin E1 degradation via proteasome. 
 
E2F1 is the pivotal transcription factor for cyclin E1 [26]. We therefore were surprised 
to observe a marked reduction in E2F1 expression (Fig. 27A and 28A) without a 
corresponding reduction in cyclin E1 mRNA levels (Fig. 27B and 28B). This prompted 
us to verify whether the expression levels of LRH1 (Liver Receptor Homolog 1), a 
known alternative transcription factor for cyclin E1 in the hepatic lineage, was affected. 
LRH1 induces also cyclin D1 expression, acting as coactivator for β-catenin/Tcf4 
complex. [27]. 
A ma
RNA 
rked decrease in E2F1 protein levels in HepG2 and HuH7 (Fig. 27A and 28A) were 
paralleled by a increase in the amount of LRH1 both at the protein (Fig. 32) and m
levels (*p<0.001, **p<0.017, compared to NT, Fig. 33). Accordingly, in JHH6, where 
the decrease of E2F1 protein level was modest compared to HepG2 and HuH7 (Fig. 27A 
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and 28A), no up-regulation, rather a down-regulation (Fig. 33, ***p<0.009 compared to 
NT) of LRH1 was observed. 
 
 
Figure 31. Liver Receptor Homolog 1. 
lineage. (Bortrugno OA et Al. Synergy between 
LRH1 and β-catenin induces G1 cyclin-
mediated cell proliferation. Molecular Cell, 
2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A marked decrease in E2F1 protein levels in HeG2 and HuH7 were paralleled by a increase in the amount of LRH1 protein, while in 
al factors were similar. 
 
To verify whether in HepG2 the reduction of E2F1 level may promote LRH1 expression 
independently of bortezomib treatment, E2F1 was depleted in non-treated cell by a 
LRH1 is an alternative transcriptional factor for 
cyclin D1 and cyclin E1 mRNAs in the hepatic 
Figure 32. Representative western blot of transcriptional factor LRH1. 
JHH6 the protein levels of both transcription
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specific siRNA and the expression levels of LRH1 and E2F1 monitored. The data 
reported indicate that despite the marked reduction of E2F1 mRNA level compared to 
pared to siGL2), no up-regulation of LRH1 mRNA was 
e also in JHH6 cells. Thus, the E2F1/LRH1 inverse 
bserved in HepG2 most likely represents a bortezomib-induced effect (see 
[28]). 
 
 
 
Figure 33. LRH1 mRNA levels in HCC cell lines. 
 paralleled by a increase in the amount of LRH1 both at the 
 27A and 28A), no up-regulation, rather a down-regulation 
(***p<0.009, compared to NT) of LRH1 was observed. The results are expressed as means ±SEM, n=6.  
 
controls (p<0.0001, com
observed. Notably, this was tru
relation o
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A marked decrease in E2F1 protein levels in HepG2 and HuH7 were
protein (Fig. 32) and mRNA levels (*p<0.001, **p<0.017, compared to NT). Accordingly, in JHH6, where the decrease of E2F1 
protein level was modest compared to HepG2 and HuH7 (Fig.
2.2.7 Effect on cell viability of a combined administration of bortezomib and siE2F1 
The reported data suggest that at least part of the bortezomib induced effects on HepG2, 
HuH7 and JHH6 occur via E2F1 down-modulation. We thus investigated whether 
siE2F1 could potentiate bortezomib effect. As reported in Figure 34, the combined 
bortezomib-siE2F1 treatment lead to an increased down-regulation of cell viability, 
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compared to the single administration of bortezomib (*p<0.004 for HepG2, **p<0.001 
for HuH7, and ***p<0.003 for JHH6, compared to NT + 20nM of bortezomib). 
This combined effect is more evident in HepG2 and in HuH7. However, in JHH6, the 
less bortezom -affected HCC cell line, the specificity of the siE2F1 potentiates the 
bortezomib effect, decreasing the cell viability of about 30%, if compared with the 
single bortezomib treatment (Fig. 34).  
 
 
 
 
 
 
The combined bortezomib-siE2F1 treatment lead to an increased down-regulation of cell viability compared to the single 
administration of bortezomib. The results are expressed as means ±SEM, n=3 (*p<0.004 for HepG2, **p<0.001 for HuH7, and 
***p<0.003 for JHH6, compared to NT+20 nM of bortezomib). 
 
In HepG2 (differentiated HCC cell line), 26S proteasome inhibition by bortezomib 
resulted in a marked decrease of protein and mRNA levels of the transcriptional factor 
E2F1 and of cyclin D1 (Fig. 27A and B), while in JHH6 (undifferentiated HCC cell 
line), no major variations were observed (Fig. 29A and B). Results in HuH7 (low 
ib
 
 
 
 
 
 
 
 
 
 
 
Figure 34. The combined effect of bortezomib-siE2F1 administration. 
2.2.8 The peptidylproline cis-trans isomerase 1 
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differentiated HCC cell line), were not so straightforward as in HepG2 and JHH6. In fact 
it was found a considerable decrease of E2F1 protein and mRNA levels, followed by the 
somerase (PPIase) that catalyzes the specific 
isomerization of Ser/Thr-Pro motifs only after phosphorylation, inducing conformational 
substrate p tic activity, 
comp NA 
damage [32- in the pathogenesis 
of some hum
ced cyclin D1 
activation ad cell transformation (Fig. 35 and 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Regulation of Pin1 expression by E2F family. 
 
decrease of cyclin D1 protein levels, and increase of mRNA content (Fig. 28A and B). In 
order to understand these data, we investigated the protein and mRNA levels of the 
peptidylproline cis-trans isomerase 1 (Pin1), involved in cyclin D1 regulation. 
Pin1 is a peptidylproline cis-trans i
changes in order to regulate the function of Pin1 substrates [29]. Depending on the 
rotein, these conformational changes can affect enzyma
phosphorylation status, protein-protein interactions, subcellular localization, or protein 
stability [30, 31]. Functionally, Pin1-catalyzed prolyl isomerization regulates such 
lex processes as cell cycle progression, transcription, and the response to D
34]. Furthermore, Pin1 has been shown to be involved 
an diseases, such as Alzheimer’s disease [35]. 
Pin1 is a E2F downstream target gene essential for Neu/Ras-indu
 
 
Oncogenic Neu/Ras signalling transactivates the PIN1 promoter through E2F activity. 
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PIN1, up-regulated by Neu/Ras signalling, enhances β-catenin and c-Jun signalling to 
transactivate the cyclin D1 gene. Furthermore, Pin1 binds to cyclin D1 and stabilizes it 
via a post-translational mechanism. It is possible that cyclin D1 also regulates Pin1 
expression via E2F in a positive feedback loop (Fig. 36) [36].  
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Regulation and functions of  peptidylproline cis-trans isomerase 1.  
 
Pin1 binds to cyclin D1 and stabilizes it via a post-translational mechanism. It is possible that cyclin D1 also regulates Pin1 
 
PIN1, up-regulated by Neu/Ras signalling, enhances β-catenin and c-Jun signalling to transactivate the cyclin D1 gene. Furthermore, 
expression via E2F in a positive feedback loop. 
2.2.8.1 Protein and mRNA levels of Pin1 
Results indicated that in HepG2 and HuH7 a considerable decrease of E2F1 protein 
levels were parallel to Pin1 and cyclin D1 decrease, while in JHH6 no major variations 
were observed for Pin1 protein levels, as expected (Fig. 37). 
Regarding to mRNA levels (Fig. 38), a down-regulation of PIN1 was detected in HepG2 
and HuH7 (*p<0.0003 and **p<7x10-7, respectively, compared to NT). Notably, in 
JHH6, no major variations were detected in E2F1 and PIN1 mRNA levels  
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esentative western blot of Pin1. 
e decreased in HepG2 and HuH7, while in JHH6 no major variations were observed.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. A repr
Pin1 protein levels wer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi
A down-regulation of  PIN1 was detected in HepG2 and HuH7. The results are expressed as means ±SEM, n=6 (*p<0.0003 and 
**p<7x10-7, respectively, compared to NT). CCND1= cyclin D1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gure 38. mRNA levels of PIN1 in HCC cell lines. 
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2.2.9 Two-color microarray-based gene expression analysis 
Two-color m les (control 
 two different 
(corresponding to the 
ted cells was 
 (corresponding to 
the red part of the light spectrum). The two Cy-labelled cRNA samples were mixed and 
rray scanner to 
visualize fluorescence of the two fluorophores after excitation with a laser beam of a 
defined wavelength. Relative intensities of each fluorophore were used in ratio-based 
 
 
 
 
 
 
Figure 39. Two
analysis. 
 
cRNAs prepared fro
versus 40 nM b
cyanine 3-CTP, (
bortezomib). Th
hybridized to a s
microarra
fluorophores after excitation with a laser beam of a defined 
wavelength. Relative intensities of each fluorophore may then 
regulated and 
 
icroarray compares cRNAs prepared from two total RNAs samp
cells versus 40 nM bortezomib-treated cells), which are labeled with
fluorophores. Fluorescent dyes used for NT control cells cRNA labelling was cyanine 3-
CTP, which has a fluorescence emission wavelength of 570 nm 
green part of the light spectrum), while for 40 nM of bortezomib-trea
cyanine 5-CTP with a fluorescence emission wavelength of 670 nm
hybridized to a single microarray that was then scanned in a microa
analysis to identify up-regulated and down-regulated genes (Figure 39). 
-color microarray-based gene expression 
m two total RNA samples (control cells 
ortezomib-treated cells), are labeled with 
NT cells), and cyanine 5-CTP (40 nM of 
e two Cy-labelled cRNA samples are mixed and 
ingle microarray that is then scanned in a 
y scanner to visualize fluorescence of the two 
 
be used in ratio-based analysis to identify up-
down-regulated genes. 
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Figure 40 reports the procedure for amplification of cRNAs. The method uses T7 RNA 
polymerase which simultaneously amplifies target material and incorporates cyanine 3-
or cyanine 5-labeled CTP. T7 RNA polymerase is extremely promoter-specific, 
catalyzes the formation of RNA in the 5’→3’ direction, and requires a DNA template. 
trol probes was 
used to normalize the hybridization measurements of the sample RNAs. 
Microarrays were performed in HepG2 and JHH6, in order to compare the differences in 
gene expression between a different phenotype and high affected by bortezomib HCC 
cell line and an undifferentiated and low affected by bortezomib HCC cell line. 
Comparisons between control versus 40 nM of bortezomib gene expression is reported 
  
 
 
Normalization of data was conducted with RNA-spike ins. An RNA spike-in is an RNA 
transcript used to calibrate measurements in a two-color microarray experiment. 
Oligonucleotide microarrays contain control probes designed to hybridize with RNA 
spike-ins. The degree of hybridization between the RNA spike-in and the control probes 
is used to normalize the hybridization measurements for the target probes. Each spike-in 
is designed to hybridize with a specific control probe on the target array. Known 
amounts of RNA spike-ins were mixed with samples during preparation. Subsequently 
the measured degree of hybridization between the spike-ins and the con
in Figure 41. 
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Figure 40. Amplification of cRNA using T7 RNA polymerase. 
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Figur
epG2  up-
re ent in 
JHH6).
 
e 
ene
regula
ma
nal  PCR 
p21 -
36), cyclin D1 (§§p<8x10-13), cyclin A2 (^p<2x10-43), and CdK2 (^^p<0.0002) mRNAs, 
compared to control. No major variations were observed for cyclin E1 and LRH1 
(NR5A2) mRNAs (Fig. 42). 
 
 
 
 
 
 
 
e 41. Comparison between HepG2 and JHH6 gene expression. 
 are more affected than JHH6 by bortezomib treatment and this fact is evident in gene expression. Red spots refer to
gulated genes, while green spots to down-regulated. Yellow spots are related to genes not differentially expressed (more evid
 Blue spots were used to normalize data by Agilent Scan B.  
were not surprised to find in HepG2 a more evident up- and down-regulation of 
s than in JHH6, induced by bortezomib treatment. Although the up- and down-
tion genes ratio is comparable in the two cell lines, not affected genes group is 
rked increase in JHH6. 
ysis of cell cycle factors monitored confirm the trend evaluated by Real Time
detection (Fig. 27B and 29B). In HepG2, it was observed a marked increase of 
waf1/cip1 (*p<9x10-16), parallel with a decrease of p53 (**p<4x10-10), E2F1 (§p<8x10
H
W
g
A
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igure 42. Comparison between Real Time PCR and Array data in HepG2. 
CDKN1B=p27kip1, TP53=p53, CCND1= cyclin D1, CCNE1= cyclin E1, CCNA2= cyclin A2, NR5A2=LRH1. The results are 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. Comparison between Real Time PCR and Array data in JHH6. 
Microarray analysis confirmed the slight decrease of E2F1 (*p<2x10-10) and increase of cycln D1 (**p<7x10-5) mRNAs. 
CDKN1A=p21waf1/cip1, CDKN1B=p27kip1, TP53=p53, CCND1= cyclin D1, CCNE1= cyclin E1, CCNA2= cyclin A2, NR5A2=LRH1. 
The results are expressed as means ±SEM, n=6. 
F
It was observed a marked increase of p21waf1/cip1 (*p<9x10-16), a decrease of p53 (**p<4x10-10), E2F1 (§p<8x10-36), cyclin D1 
(§§p<8x10-13), cyclin A2 (^p<2x10-43), and CdK2 (^^p<0.0002) mRNAs, compared to control. CDKN1A=p21waf1/cip1, 
expressed as means ±SEM, n=6. 
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Regarding to JHH6, the less sensitive cell line, it was confirmed the slight decrease of 
E2F1 (*p<2x10
2.2.9.1 p16
-10) and increase of cycln D1 (**p<7x10-5) mRNAs (Fig. 42). 
ink4a levels 
ntioned above, p16ink4a is a cell cycle inhibitor that 
 D-CdK4 complex, and in turn, G1 phase. p16ink4a is not expressed
JHH6 protein detection was not possible as in HepG2 with the same
croarray data, we observed in HepG2 no major variations in p16ink4
ib treatment (Fig. 44). This result was confirmed by we
 
As me exerts its activity inhibiting the 
cyclin  in HuH7 and in 
 antibody. Analysing 
mi a mRNA levels, 
after bortezom stern blot analysis. 
16ink4a mRNA (Fig. 44), evidencing a 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. p16i
No major vari  Regarding to mRNA 
levels, no major 007), on the right. The 
results are expr
 
 
In JHH6, nevertheless, microarray probes detect p
significant decrease after bortezomib treatment (*p<0.007). 
nk4a evaluation in HepG2 and JHH6. 
ations were observed monitoring the p16ink4a protein levels (western blot, on the left) in HepG2.
 variations were detected in HepG2, while a significant decrease was observed in JHH6 (*p<0.
essed as means ±SEM, n=6. 
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2.2.9.2 Pin1 levels 
Microarray data were also used to compare mRNA analysis by Real Time PC
45. Comparison between Real Time PCR and Array data for PIN1. 
A considerable decrease of Pin1 mRNA was detected in HepG2. The results are expressed as means ±SEM, n=6 (*p<0.004)
D1= cyclin D1. 
.9.3 Effects of bortezomib on EEF1A levels 
 discovered in HepG2 and JHH6 a significant increase of EEF1A1 mRNA levels
mpared to normal liver, while a marked increase of EEF1A2 mRNA was detected
R of Pin1 
(Fig. 38). A considerable decrease of Pin1 mRNA was detected in HepG2 (*p<0.004), 
re observed in JHH6 (Fig. 45). 
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while no variations we
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C
2
We  
o  in 
HH6 only (Fig. 2 and 3). Microarray data evidenced an increase of EEF1A2 mRNA (40 
nM of bortezomib, *p<0.02). in JHH6 (Fig. 46). 
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Figure 46. EEF1A 
Microarray NA levels in JHH6, 
comparing both NT s observed in JHH6-
treated cells (40 nM
 
 
Comp e PCR (only 
 of EEF1A1 (*p<0.004) compared to 
served in Real Time PCR and microarray data. 
 
 
 
Figure 47. Comparison between Real Time 
Comparison between EEF1A1 and EEF1A2 
mRNAs detected by Real Time PCR evidenced 
to control, confirming microarray array data. 
The results are expressed as means ±SEM, 
 
 
 
mRNA levels in HepG2 and JHH6. 
 data revealed an increase of EEF1A1 mRNA levels in HepG2 and an increase of EEF1A2 mR
 cell lines, confirming our results (Fig. 2). Regarding to EEF1A2, a significant increase wa
 of bortezomib, *p<0.02). The results are expressed as means ±SEM, n=6. 
arison between EEF1A1 and EEF1A2 mRNAs detected by Real Tim
for HepG2), is reported in Figure 47. An increase
control, was ob
PCR and Array data for EEF1A1/2 in HepG2. 
an increase of EEF1A1 (*p<0.004) compared 
n=6. 
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t increase was observed in JHH6, compared to controls (Fig. 48), after
b treatments. Detection of both eEF1A1 and eEF1A2 proteins (eEF1A) is 
 
Regarding to protein levels, a marked decrease of eEF1A2 was found in HepG2, while a 
significan  
bortezomi
reported. 
 
 
 
 
 
 
 
 
Figure 48. eEF1A2 protein levels in HepG2 and JHH6. 
 marked decrease of eEF1A2 was found in HepG2, while a significant increase was observed in JHH6, compared to controls, after 
ortezomib treatments. Detection of both eEF1A1 and eEF1A2 proteins (eEF1A) is reported. 
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There is a growing evidence of the involvement of components of the translation 
machinery in the development of cancer. In particular, the protein elongation factor 
eEF1A2 has been identified as an important player in many human tumors [1-3]. Despite 
these observations, no information are so far available on its possible contribution to the 
biology of hepatocellular carcinoma [4].  
We show that the mRNA levels of both EEF1A1 and EEF1A2 are dramatically 
increased in the JHH6 cells compared either to the normal liver or HepG2 and HuH7 
cells (Fig. 2). Since the differentiation grade decreases from HepG2 to HuH7 and JHH6 
[5, 6], it is tempting to speculate that there might be a direct correlation between the 
mRNA levels of eEF1A1/2 and the neoplastic phenotype of hepatocellular carcinoma 
cells. It is possible that a more undifferentiated HCC cell needs higher amount of eEF1A 
mRNA to sustain a prompt protein synthesis, possibly required in cell proliferation and 
in the organization of cytoskeleton [7], both crucial aspects for an actively 
cycling/migrating cell. 
Whereas only one of the two eEF1A forms is normally expressed in non transformed 
cells [8] in the HCC cell lines considered, we observed the contemporary elevation of 
the two EEF1A mRNAs, a phenomenon particularly marked in JHH6 cells (Fig. 2). This 
observation may in part depend on the parallel gene amplification detected for both 
EEF1A1 and EEF1A2 (Fig. 3). In fact, the modest extent of amplification can hardly 
account for the dramatic increase of the mRNA levels observed, especially in JHH6 
cells. A better insight about this observation will come from the evaluation on the 
expression levels of eEF1A forms in an appropriate number of HCC biopsies from 
patients.  
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The increased mRNA expression of EEF1A genes in JHH6 with respect to HepG2, is 
paralleled by an increased of nuclear-enriched/cytoplasm protein ratio (Fig. 3A and 3B) 
in JHH6 (#p=0.038) compared to HepG2. The fact that by means of the nuclear protein 
extraction procedure the cytoskeleton sedimentation occurs, and with it sediments the 
eEF1A1 bound to actin [9, 10], may suggest that in JHH6, the higher levels of 
cytoskeleton-bound eEF1A1 are required for the non-canonical function of this protein 
in cytoskeletal organization [9]. The higher mRNA levels detected for eEF1A1 
compared to normal tissue and HepG2 cells may thus represent a reservoir usable not 
only for a prompt protein synthesis but especially for cytoskeleton remodeling. As the 
antibody used to detect eEF1A does not discriminate between the two forms of the 
protein, we cannot exclude that part of the elevation of the nuclear-enriched amount of 
eEF1A may depend on eEF1A2 too (Fig. 4). Moreover, the dramatic elevation in 
eEF1A2 mRNA level favors the hypothesis that in JHH6, eEF1A2, at least indirectly, 
contributes to modulate cytoskeleton organization [11]. 
The different expression levels and/or the sub-cellular localization [11-14] of eEF1A 
have been related to cell proliferation in different cell types. In subconfluent HCC-
derived cells, no significant differences were noted in cell growth rate (evaluated by 
DNA synthesis) and the expression of different cyclins and of the transcription factor 
E2F1 [12]. Thus, the different levels observed for p16ink4a and p27kip1 in JHH6 compared 
to HepG2 (Fig. 6) may not have a functional meaning, at least within the experimental 
conditions used.  
Since no detectable differences in the growing rate were evident in subconfluent cells, 
we speculated that differences might have arisen under not optimal growth conditions, 
such as those represented by prolonged culturing time where the marked increase in cell 
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number determines an increase of toxic metabolites and a decrease of nutrients per cell. 
A more pronounced attitude of HepG2 compared to JHH6 to exit cell cycle was 
observed between 2 and 4 days after reaching confluence as indicated by the staining for 
the senescence associated β-gal (Fig. 9). The fact that the exit from the cell cycle of 
HepG2 occurred some days after reaching confluence, suggests a minor contribution of 
cell contact inhibition to the escape from cell cycle. 
The negligible number of JHH6 cells positive for the β-gal associated senescence 
staining suggests that these cells tend to be more resistant than HepG2 to 
aging/senescence and may have extended life capacity, a feature of aggressive cancer 
cells. Thus, in contrast to what reported in another cell type [13], in the hepatic cell line 
JHH6 the over-expression of EEF1A genes correlates with higher proliferation ability 
only under non optimal growing conditions either by activating cell survival 
mechanisms or by affecting cytoskeletal organization. Translated to the in vivo 
condition, this feature may confer to the cells a more aggressive tumor phenotype 
allowing the proliferation in areas of the tumor far from vessels were nutrients and 
oxygen concentration are reduced. It should be noted that, despite the relation observed 
between EEF1A gene expression and the proliferative features of JHH6 and HepG2, we 
cannot exclude that other biological factors can contribute to the different proliferation 
features observed. 
The relation between eEF1A1/2 expression and apoptosis shown in other experimental 
models [14] prompted us to investigate this biological aspect in the HCC cells studied. 
In sub-confluent cells we did not detect any significant difference in apoptotic rate 
between JHH6 and HepG2 cells in the presence/absence of growth factors and when 
treated with a known pro-apoptotic agent such as staurosporin [12]. In some cases 
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increased eEF1A expression has been shown to favor apoptosis upon serum deprivation 
[15, 16], in other to protect [16, 17]. These observations together with our data seem to 
indicate a different cell specific relation between eEFA1/2 expression and apoptosis. 
The data here reported indicate that in the hepatic cell lines used, HepG2, HuH7 and 
JHH6, bortezomib markedly reduces the amount of living cells (Fig. 11, 12, and 13) in a 
dose-dependent manner. Notably, this effect is less pronounced in JHH6 compared to 
HepG2 and HuH7 at low bortezomib concentration (20 nM). Moreover, it is evident an 
overall more contained increase of the necrotic marker LDH (Fig. 15) in JHH6 
compared to HepG2 and HuH7. Finally, cell viability is constantly higher in JHH6 
compared to other cell lines (Fig. 18). We can reasonably exclude a reduced bortezomib-
mediated inhibition of the proteasome in JHH6 cells compared to HepG2 as similar 
decrease of proteasome activity was detected in the two cell lines (Fig. 11). These 
findings are in favour of a reduced sensitivity of JHH6 to bortezomib effects. Thus, HCC 
cell response to bortezomib is likely influenced by cell phenotype with possible 
clinical/therapeutic consequences. 
In our experimental set up, beside inducing apoptosis (Fig. 20, and 22) in accordance to 
what detailed elsewhere [18-20], bortezomib promotes a potent anti-proliferative effect. 
Whereas in HepG2 and HuH7 this effect is detectable already at 20 nM, in JHH6 it is 
relievable at 40 nM, once again showing a reduced effect of bortezomib on JHH6 (Fig. 
23, 24, 25 and 26). Notably, the effects on cell cycle distribution are similar in the three 
cell lines at 40 nM of bortezomib. A marked decrease of S phase cells, is paralleled by 
an increase of G2/M phase cells with no major variation in G1 and G0 phase cells. These 
effects seem to be cell type specific as, for example, in prostate tumor cell PC-3 [21], in 
squamous cell carcinoma cell lines SCC [22] and in Ewing’s sarcoma derived cells [23], 
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bortezomib induced an increase of both S and G2/M phase cells. Regarding to HuH7, it 
was shown a marked increase of G1/G0 phase cells at 20 nM of bortezomib (Fig. 25). 
This fact could be related to the absence of G1 cell cycle inhibitor p16ik4a, as reported in 
Figure 7 and previously evidenced [24].  
The decrease of S phase and the accumulation of G2/M phase cells observed is consistent 
with the expression levels of the cell cycle regulators considered. In HepG2, a marked 
reduction of the major G1 and G1/S regulators such as cyclin D1, the transcription factor 
E2F1, the hyper-phosphorylated form of the retinoblastoma protein and the increase of 
the cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 (Figure 27A and 27B), 
prevent the cells to go through the G1 phase thus determining a drastic reduction in the 
amount of S phase cells. The reduction of cyclin A2 and the increase of p21waf1/cip1 [25], 
positive and negative regulators of G2/M progression, respectively, can justify the G2/M 
accumulation. Thus, in HepG2, a pathway through which bortezomib induces cell cycle 
arrest involves the increase of the levels of p21waf1/cip1 and  p27kip1 which, in turn, inhibit 
the biological functions of the various cyclin/CdK complexes (see Fig. A for a scheme). 
Notably, as p21waf1/cip1 transcriptional activation does not go in parallel with an increase 
of p53 protein levels (Fig. 27A), a p53-independent up-regulation of p21waf1/cip1 seems to 
occur. Finally, we cannot exclude the contribution of p16ink4a to cyclin D1-CdK4 
complex inhibition, as evidenced in Figure 44. 
In addition to promote p21waf1/cip1 and  p27kip1 up-regulation, bortezomib-induced cell 
cycle arrest is reinforced by the down-regulation of the transcription factor E2F1. This, 
in turn, leads to the transcriptional down-regulation of the E2F1 target genes cyclin D1, 
cyclin A2, CdK2 and to the reduction in the amount of the phosphorylated form of the 
retinoblastoma protein (Fig. 27B). 
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Figure A. A molecular model suggested on HepG2 cell line. 
Cell cycle arrest is induced by increasing the levels of p21waf1/cip1 and  p27kip1  which in turn inhibit the biological functions of the 
various cyclin/CdK complexes. Moreover, E2F1 transcript and protein amounts are reduced thus resulting in the transcriptional 
down-regulation of the E2F1target genes cyclin D1, cyclin A2 and CdK2 and E2F1 itself. 
 
Notably, an siRNA-mediated depletion of E2F1 induces similar variations in the levels 
of E2F1-target genes [26] and in the amount of the phosphorylated form of pRB. This 
observation favors the idea that bortezomib-induced variation of E2F1 related genes is 
indeed dependent of E2F1 down-regulation. 
HuH7 has a low differentiated HCC phenotype and this feature was clear evident after 
bortezomib treatments. A decrease of E2F1, of the hyper-phosphorylated form of pRB, 
of cyclin A2, and in minor part of CdK2, while an increase of p21waf1/cip1 were detected 
(Fig. 28A and 28B), as observed in HepG2. Regarding to cyclin D1 and p27kip1, a similar 
behaviour as in JHH6 (see below), was observed. 
In JHH6, an overall less pronounced modification of the expression of the cell cycle 
regulators considered was observed (Fig. 29A and 29B). In particular, no major 
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variations in the protein levels of cyclin D1, CdK2 and p27kip1, a more contained 
reduction of cyclin A2 and E2F1, the hyper-phosphorylated form of pRB and a more 
modest p21waf1/cip1 elevation were observed. Despite these differences, a clear block of 
cell proliferation was evident. Whereas this may be due to an increased sensibility of 
JHH6 to the level variations of these cell cycle regulators, other mechanisms cannot be 
excluded. 
In this regards, the reduction of LRH1 levels (Fig. 32 and 33), a gene product implicated 
in cell proliferation and tumorigenesis [27, 28] may contribute to explain JHH6 growth 
arrest. In HepG2, despite the marked reduction of the amounts of E2F1-pRB, a cellular 
circuit known to promote cyclin E1, and indirectly cyclin D1 expression [29, 30], no 
decrease of cyclin E1 mRNA levels were observed (Fig. 27B and 33). Our data indicate 
that cyclin E1 mRNA amounts may be maintained similar to that of non-treated cells by 
the increased expression of LRH1 (Fig 32 and 33), a protein shown to act as a cyclin E1 
transcription factor in the hepatic lineage [30]. Interestingly, in HuH7, where the down-
regulation of the E2F1-pRB circuit was similar, a major increase of LRH1 protein and 
mRNA was observed (Fig. 32 and 33) compared to HepG2. This fact could explain not 
only the cyclin E1 mRNA amounts observed, but also the increase of cyclin D1 mRNA 
detected (Fig. 28B). 
In JHH6, where the down-regulation of the E2F1-pRB circuit was less pronounced than 
in HepG2 and HuH7, LRH1 expression was not increased but reduced. Thus, upon 
bortezomib-induced de-regulation of cell cycle mediators, the hepatic cell HepG2 and 
HuH7 seem to react by trying to maintain cyclin E1 synthesis via an inverse expression 
of E2F1 and LRH1. The reasons for the cellular necessity to keep cyclin E1 mRNA 
levels constant upon bortezomib treatment remain to be clarified. A possibility is that 
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proper cyclin E1 is required to minimize hepatic cell apoptosis. In this regard, cyclin E1 
depletion by siRNAs induced a marked apoptosis in HepG2 [31].  
Rather then being a general phenomenon, the up-regulation of LRH1 following E2F1 
protein decrease in HepG2 and HuH7 seems to be a bortezomib-dependent effect. 
Indeed, upon siRNA-mediated depletion of E2F1 (siE2F1) no up-regulation of LRH1 
was observed in HepG2 and also confirmed in JHH6 [26]. It is thus possible that, in 
HepG2 (but probably also in HuH7), the E2F1/LRH1 circuit might represent a pro-
survival mechanism triggered by un-favorable survival conditions, i.e. bortezomib 
treatment. 
Beside being useful to better characterize the cyclin E1-LRH1-E2F1 circuit, the siE2F1 
allowed us to prove that it can be used to potentiate bortezomib effects on cell viability 
(Fig. 34). This observation may potentially open the way to an HCC therapeutic 
approach based on the combined administration of the siE2F1 and bortezomib, a strategy 
which could reduce bortezomib dosage and thus side effects. This observation may be 
particularly helpful for HCC cell types which show reduced bortezomib sensitivity such 
as JHH6. 
One mechanism involved in JHH6 survival could be represented by the relation between 
E2F1-Pin1-cyclin D1. Maintenance of Pin1 and cyclin D1 levels are related to E2F1 
activity. In addition, Pin1 contributes to cyclin D1 stabilization that in turn, creates a 
positive loop that stimulates E2F1 activity again, increasing survival (Figure 37, 38 and 
45) [32].  
The second mechanism could be related to the increase of eEF1A2 expression. We have 
reported that this factor is dramatically over-expressed in JHH6, the more tumorigenic 
cell line, compared with normal liver, HepG2 and HuH7 (Fig. 2). eEF1A2 mRNA and 
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protein levels are increased in JHH6 after bortezomib treatments (Fig. 46 and 48 
respectively). It is tempting to speculate that eEF1A2 expression could lead to an overall 
increase in protein translation and an increase in bulk protein synthesis, enhancing JHH6 
replication. Since cell division requires sufficient protein production to fulfill the 
metabolic and size requirements of two new daughter cells, it is hard to understand, 
however, how eEF1A2 could up-regulate the production of specific proteins related to 
cell survival, and further investigations occur [33]. It is a fact, nevertheless, that 
EEF1A2 gene silencing reduced cell viability as well as proliferation and increased 
apoptosis rates in HCC cell lines [34].  
In conclusion, we have shown that in the HCC cell lines HepG2, HuH7 and JHH6, 
EEF1A1 and, in JHH6 only, EEF1A2 are over-expressed when compared to normal liver 
tissue and that this only in part depends on gene amplification. Moreover, the increased 
nuclear-enriched/cytoplasmic protein ratio of eEF1A and the marked raise of both gene 
expression detected in JHH6 do not relate with apoptosis resistance. Finally, the 
increased eEF1A expression is associated with an higher proliferation capacity in the 
undifferentiated JHH6 under sub-optimal growth conditions only. Future studies in HCC 
biopsies will contribute to further clarify the significance of eEF1A in the biology of 
hepatocellular carcinoma and will indicate its possible role in tumour aggressiveness. 
Our data show the mechanisms regulating cell toxicity and proliferation inhibition 
effects of bortezomib on the HCC cell lines JHH6 and HuH7, expanding the knowledge 
on HepG2. The different phenotypes, hepatocyte-like for HepG2, low differentiated for 
HuH7 and undifferentiated for JHH6, together with the less overall effect of bortezomib 
on JHH6, suggests that in vivo not all HCC forms may respond similarly to bortezomib 
treatment. Despite this fact, the potent pro apoptotic effect reported [19], the cytotoxic 
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and anti-proliferative actions here described together with the in vitro observed 
negligible toxicity on normal human hepatocytes [34], make of bortezomib an attractive 
candidate for future experimentation in animal models, alone or in combination with 
specific molecular-targeted drugs, such as siRNA, possibly leading to a novel treatment 
for HCC. 
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4.1 Cell cultures 
HepG2 and Hela cell lines were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Euroclone, Celbio, Devon, UK); JHH6 and HuH7 [1], derived from Japan 
Health Science Research Resources Bank (HSRRB, JCRB1030 depositor Dr. Nagamori, 
S). JHH6 and HuH7 were cultured in William’s medium E (Sigma-Aldrich, St Louis, 
Mo, USA) and Dulbecco’s modified Eagle’s high glucose medium DMEM (Euroclone, 
Celbio, Devon, UK), respectively. All media contained 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Euroclone, Celbio, 
Devon, UK).  
HepG2, HuH7 and JHH6 were assigned to high, medium and low hepatocyte 
differentiation grade on the basis of their capacity to synthesize albumin, a known 
marker of hepatic differentiation [2]. HepG2 and HuH7 displayed 3.6±1.6 and 1±0.1 
albumin mRNA content, respectively, whereas no albumin mRNA was detected in JHH6 
(data not shown). However, JHH6 were able to synthesize ferritin, thus showing a 
residual hepatic phenotype (data not shown).  
 
4.2 RNA and DNA extraction (EEF1A1/2 genes) 
Total RNA and DNA were extracted from 2 x 106 cells cultured near confluence by 
using Tri-reagent procedure (Sigma Chem. Co. St.Louis, MO, USA) and suspended in 
50 µl of DEPC water or in an adequate volume of 8 mM NaOH, respectively. The 
quality and integrity of total RNA and DNA were evaluated by both gel electrophoresis 
and spectrophotometric determination (Spectra Max plus 384, Molecular Devices). 
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4.3 cDNA synthesis (EEF1A1/2 genes) 
The samples were treated with amplification grade DNase I (Sigma Chem.Co, St.Louis) 
following the producer’s protocol and directly used for reverse transcription. 2 µg of 
total RNA solution were incubated at 80°C for 10 min and then at 25°C with 0.01 mg/ml 
random hexamers (Pharmacia, Biotech, Uppsala, Sweden) for 10 min. Subsequently, 
reverse transcription was performed as described above. 
 
4.4 Quantification of the mRNA levels and gene amplification for EEF1A1/2 
Real Time PCR was performed in single-plex reactions (7900/HT Sequence Detection 
System - Applied Biosystems). The primers used are reported in Table 2, while Table 3 
reports primers used for gene amplification. All amplifications were conducted in a final 
volume of 25 µl of SYBR/Master Mix buffer (Applied Biosystems-Applera 
Corporation,USA), containing primers (300 nM each), SYBR green, dNTPs (200 mM 
each), Taq DNA polymerase and 1 µl of cDNA reverse transcription solution. 28S 
rRNA, EEF1A1 and EEF1A2 were submitted to 40 cycles of amplification with enzyme 
activation at 50°C for 2 min, pre-denaturation at 95°C for 10 min, denaturation at 95°C 
for 15 sec, annealing and extension at 62° for 60 sec. EEF1A1, EEF1A2, and 28S rRNA, 
were analyzed for each samples in a unique plate to assure the same amplification 
efficiency. The samples were treated by DNase prior to perform reverse transcription in 
order to completely exclude the possibility that amplicons of EEF1A could derived from 
non-actively transcribed retropseudogenes [3]. 
The relative amounts of the mRNA of target genes were normalized by 28S rRNA 
content. 
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Table 2. EEF1A1/2 Real Time PCR primers pair. 
GenBank Number mRNA Primer pair Amplification Region Length (bp)
NM_001402 EEF1A1 
(FwEF1A) 5’-AACATTGTCGTCATTGGACA-3’ 
(RvBL5) 5’-ACTTGCTGGTCTCAAATTTC-3’ 88-316 228 
NM_001958 EEF1A2 
(FwEEF1A2) 5’-GCCACCGTCAATAGGTGGAC-3’ 
(Rv3) 5’-TGATGTGGGTCTTCTCCTTG-3’ 9-191 182 
M11167 28S rRNA 
(Fw28S) 5’-TGGGAATGCAGCCCAAAG-3’ 
(Rv28S) 5’-CCTTACGGTACTTGTTGACTATCG-3’ 282-365 83 
 
Table 3. EEF1A1/2 gene amplification primers pair. 
GenBank 
Number DNA Primer pair Restriction digestion Length (bp)
J04617 EEF1A1 
(FwEF1A) 
5’-ACATTGTCGTCATTATCGAC -3’ 
 
RvEEF1A1 DNA-I 
5’-TTGATCTTTCCCTTTCTGGT-3’ 
MnII + 102 + 49+ 39 + 9 151 
AF163763 EEF1A2 
FwEEF1A2 DNA  
5’-ACCAAACATGGGGGCTTGGT-3’ 
 
RvEEF1A2 I-E  
5’-TGATGTGGGTCTTCTCCTTG-3’ 
PstI 134 + 71 206 
 
4.5 Bortezomib experimental set up 
Unless otherwise indicated, in all the experiments the cells were seeded at 3.8x103 
cells/cm2 in 6-wells plate, allowed to adhere 24 hr, cultured for two days in the presence 
of complete medium and bortezomib (once administered). The bortezomib was in the 
commercial form Velcade (Janssen-Cilag International N.V. – 0.09 mg Bortezomib/1 
mg Velcade), resuspended in phosphate buffer saline solution (PBS). 
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4.6 Assay for proteasome activity 
Cells were collected, disrupted (by three freezing/thawing steps using liquid nitrogen) in 
10 volumes of HEPES buffer (25 mM, pH 7.5) containing: 2.5 mM MgCl2, 0.5 mM 
DTT and then centrifuged at 10000xg for 30 min, all at 4°C [4]. Sixty µg of proteins 
were resuspended in 250 µl of HEPES buffer containing ATP (GE Healthcare, 5 µM) 
and Suc-LLVY-AMC proteasome 26S substrate (BostonBiochem, 1 mM). The reaction 
was run for 45 min at 37°C, quenched by adding 250 µl ice-cold ethanol and filled up to 
1.5 mL with H2O. Each sample was read in triplicate using a 96-black wells microtiter 
plate (Plate Chamaleon - Hidex). Inhibition of 26S proteasome activity by bortezomib 
was calculated comparing the fluorescence value of the maximal proteosome activity 
(non-treated cells control) with the fluorescent values of bortezomib-treated cells using 
the Mikro Win 2000 software. 
 
4.7 Cell morphology and count 
The evaluations of cell morphology and number were made by direct microscopic 
observation (Nikon Eclipse TS100) and with Thoma’s haemocytometer chamber, 
respectively.  Cell viability was evaluated by 0.05% trypan blue dye staining (w/v in 
PBS) (1:1, v/v). Total viable cell number was calculated by the formula: 
                                                           Xn = N° x 2 x 104 
where Xn is the cell number in 1 ml of sample, N° is the viable cells number, 2 is the 
dilution factor with trypan blue dye and 104 is the Thoma’s haemocytometer conversion 
factor. 
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4.8 Measurement of HepG2 colony number and area 
Cells were washed gently by PBS, then fresh medium was added before analysis by an 
inverted microscope (Leica Mycrosystem, Wetzlar, Germany). Colony morphometrical 
analysis and number were calculated using the Sigma Scan Pro program, considering 
five fields for each treatment, each containing at least 20 events (magnification = 5x). 
 
4.9 Cytotoxicity assays 
Extracellular lactate dehydrogenase (LDH) was evaluated by a kit (BioVision Prod., 
Mountain View CA) according to manufacturer instructions. 100 µl of cells supernatant 
were transferred into an optically clear 96-well plate in triplex and added with 100 µl of 
reaction solution (containing Catalyst/Dye solutions at 1/45 proportions). Samples were 
incubated for 30 min at room temperature protecting plate from light exposure. 
Detection of LDH enzyme amount was performed at 500 nm using a spectrophotometer 
(Spectra Max plus 384, Molecular Devices). As positive control, triton X-100-treated 
cells (at 1% final concentration) was used; free medium represented the negative control. 
The percentage of cytotoxicity was calculated applying the formula: 
(test sample – negative control) 
x100 
(
Cytotoxicity (%) =  
positive control – negative control)  
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4.10 Cell viability assays 
MTT assay was performed in 96-wells microtiter plates, where cells were seeded at 
1.25x103/well and 0.6x103/well for the 2 and 6 days assay, respectively, in 200 µl of 
complete medium. After 24 hr of incubation, bortezomib was added directly to the 
medium. Each sample was analysed in triplicate. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT, Sigma-Aldrich, St Louis, Mo, USA) test was 
conducted according to standard procedures, adding 25 µl (4 mg/ml) of MTT solution 
for each well directly. After 4 hr cell viability was monitored at 590 nm 
spectrophotometrically (Spectra Max plus 384, Molecular Devices). 
 
4.11 Apoptosis evaluation 
Apoptosis was evaluated by the Annexin V test (Bender – Med System, Burlingame, 
CA) and propidium iodide (PI) staining (BD Pharmingen) according to manufacturer’s 
instructions. Briefly, cells were seeded at 3.8 x103 cells/cm2 in 6 wells plates and kept in 
complete medium for 2.5 days (70% confluent cells) or in complete medium overnight 
and then in serum-free medium (starved cells) for two days. The cells were then 
collected, resuspended in binding buffer at the concentration of 2-5x105 cell/ml and 
incubated with annexin V antibody for 15 min. Cells were then sedimented, resuspended 
in the binding buffer and incubated with propidium iodide for 20 min at room 
temperature. After a final washing step, cells were resuspended in 0.5 ml of PBS/0.5% 
BSA (bovin serum albumin) and analyzed by flow cytometry (FACSCanto, BD) using 
the DIVA software.  
Annexin V positive cells were considered apoptotic, events positive for propidium-
iodide only were considered cellular debris. As positive control, an aliquot of cells kept 
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in complete medium was treated with 1 µM staurosporin (Sigma Chem.Co, St.Louis) for 
3 hr prior to harvesting. 
 
4.12 Cell cycle phases evaluation 
Cell cycle phases can be evaluated by the measurement of bromodeoxyuridine (BrdU) 
incorporation into newly synthesized DNA and propidium iodide staining. Moreover, to 
distinguish between G0 and G1 phase cells, Ki-67 test was performed. Ki-67 is a nuclear 
cell proliferation-associated antigen expressed in all cell cycle phases except G0 stage 
[5]. The cells were seeded at 3.8 x103 cells/cm2 in 6 wells plates and 20 hr before 
harvesting (70% confluent cells), they were pulsed with bromodeoxyuridine (BrdU) at a 
final concentration of 10 µM. Cells were prepared for BrdU staining by resuspension in 
70% ice cold Et-OH over night. After a washing step with PBS/0.5% BSA, the cells 
were treated with 1M HCl/0.5% BSA for 1 hr. After another washing step, the cells were 
resuspended in 0.1 M Na2B4O7 pH 8.5 for 2 min and then washed again with PBS/0.5% 
BSA. Each sample was incubated with fluorescein-isothiocyanate (FITC) – conjugated 
mouse monoclonal antibody (BD PharMigen) anti-BrdU for 1 hr. As background 
control, one sample was incubated with fluorescein-isothiocyanate (FITC) – conjugated 
mouse IgG1 Isotype Control. After a washing step, the samples were incubated with 4 µl 
PI Staining Solution (BD Pharmingen) and 100 µl Ribonuclease A 100 µg/ml (Sigma) 
for 1 hr. Cells, resuspended in PBS containing 0.5% BSA, were analyzed by flow 
cytometry (FACScanto, BD) using the DIVA software. Ki-67 staining (BD PharMigen) 
was performed according to manufacturer instructions.  
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4.13 Proliferation assay 
Senescence associated test [6] was performed between one and four days after cells 
reached confluence. At seeding a sterile cover glass for microscopy was placed on the 
bottom of a 3 cm diameter well dish. At different time points, the cells on the cover glass 
were rapidly washed with PBS and fixed with 2 ml of Fixation Solution (2% w/v 
Formaldehyde, 0.2% w/v Glutaraldehyde in PBS) for 20 min. Subsequently, cells were 
quickly washed twice with PBS and covered with 2 ml of Staining Mixture. The staining 
mixture was obtained adding to a previously prepared Staining Solution (40mM Sodium 
Citrate/Orthophosphoric acid, pH 6; 150 mM NaCl; 2 mM MgCl2) Potassium 
Exacianoferrate (II) and Potassium Exacianoferrate (III), to reach a final concentration 
of 5 mM, and X-Gal (Sigma) at a final concentration of 1g/l. Staining was performed 
over night in the dark at 37°C. Subsequently, the supernatant was removed, cells rapidly 
washed twice in PBS, then in H2O and finally over-layered by a drop of glycerol. The 
cover glass was fixed on a microscopy slide with cells turned over the glycerol drop (to 
avoid air bubble formation). After 30 minutes of gentle heating at 37°C to dry any 
excess of water, cover glasses were sealed and analysed by microscope. 
 
4.14 Protein extraction procedures 
Protein extracts were prepared from aliquots of 6x106 subconfluent (70% confluent) 
cells that were washed with phosphate buffer saline solution (PBS) and lysed as 
described by Mansilla et al. [7]. 
Cytoplasmic and nuclear-enriched extracts were prepared as described by Scaggiante et 
al. [8]. Cells were resuspended in 400 µl/106 cells ice-cold 10 mM Hepes pH 7.9, 1.5 
mM MgCl2, 10 mM KCl (solution A) containing 1 mM dithiotreitol, 1 mM 
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phenylmethylsulphonyl fluoride, and 0.05% Nonidet P-40. After 10 minutes of 
incubation on ice, the cells were controlled by trypan blue dye incorporation to monitor 
membrane cell disruption and, if necessary, the incubation time was increased up to 
reach 90% cell dye inclusion. The cells were then centrifuged at 800xg for 5 minutes at 
4°C, the supernatant containing the cytoplasm was collected and the pellet was rinsed 
once with solution A without Nonidet P-40. The cytoplasmic extract was complemented 
with 0.5 M NaCl, 25% glycerol and 0.2 mM EDTA (final concentrations) and stored in 
small aliquots at -80°C. The pellet containing nuclei was resuspended in 80 µl/106 cells 
ice-cooled solution B (20 mM Hepes, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 25% glycerol) containing 1 mM dithiotreitol and 1 mM phenylmethylsulphonyl 
fluoride. After 20 min incubation on ice with constant stirring, the suspension was 
vortexed for 60 seconds, then centrifuged at 10000xg for 10 minutes at 4°C. The 
supernatant containing nuclear-enriched extract was recovered and stored in small 
aliquots at -80°C.The protein concentration was evaluated by BCA protein assay reagent 
(Pierce, Rockford, IL). 
 
4.15 Western blotting  
Western blotting was performed with 20-40 µg of  proteins separated by 12% SDS-
PAGE, and transferred onto a 0.22 µm nitrocellulose membrane (Schleicher & Schuell, 
Keene, NH). The antibodies used were: mouse anti-eEF1A (0.5 µg/ml) (Upstate 
Biotechnology, Lake Placid, NY); mouse anti-EF1A2 (Abnova); mouse anti-p21waf1/cip1 
(0.7 µg/ml), mouse anti-p27kip1 (1 µg/ml), mouse anti-p53 DO-1 (0.4 µg/ml), mouse 
anti-CdK 2 (1 µg/ml), rabbit anti-cyclin D1 (0.4 µg/ml), rabbit anti-cyclin A (0.4 µg/ml), 
rabbit anti-SRF (0.7 µg/ml) and rabbit anti-GAPDH (0.2 µg/ml) (Santa Cruz 
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Biotechnology, California, USA); mouse anti-p16ink4a (2 µg/ml), mouse anti-cyclin E1 
(0.5 µg/ml), mouse anti-E2F1 (5 µg/ml), mouse anti-RB (1.25 µg/ml), mouse anti-PARP 
(0.5 µg/ml) (BD Bioscience Pharmingen San Jose, California, USA). Antibody rabbit 
anti-pin1 was gently gifted by  prof. G. Del Sal (Dept. of Life Sciences, University of 
Trieste, Italy).  
After incubation, the corresponding secondary horseradish peroxidase antibodies was 
used (Santa Cruz Biotechnology). The blots were developed by using an enhanced 
chemiluminescent substrate (Supersignal West Pico, Pierce, Rockford, IL). 
For each protein considered, al least three independent western blottings were 
performed. 
 
4.16 Quantification of mRNA levels, RT-PCR and Real Time PCR  
Total RNA was extracted using RNeasy Mini kit (Qiagen S.p.A., Italy). The quality, 
integrity and quantification of total RNA was evaluated by spectrophotometric 
determination using a Lab-on-Chip-System Bioanalyzer 2100 (Applera Corporation, 
USA) and a NanoDrop ND-1000 (CelBio, Euroclone, Italy). Reverse transcription was 
performed with 1 µg of total RNA by oligo-dT16 and murine myeloblastosis virus 
reverse transcriptase (Applera Corporation, USA), using the master mix solution 
reported on Table 4. Real Time PCR was performed in triplicate in a final volume of 10 
µL of SYBR/Master Mix buffer (Applied Biosystems-Applera Corporation,USA), 
containing primers (300 nM each), SYBR green, dNTPs (200 mM each), Taq DNA 
polymerase and 1 µl of cDNA reverse transcription solution. (7900/HT Sequence 
Detection System - Applied Biosystems). The primers (300 nM, MWG Biotech, GA) 
used to detect cell cycle regulators by Real Time PCR are reported in Table 5. Primers 
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annealing temperature and specific amplification products were first evaluated by step-
gradient PCR and gel electrophoresis. 
 
Table 4. Reverse transcription Master Mix 
Component Final concentration 
25 mM MgCl2 solution 5 mM 
10X PCR Buffer II 1X 
Oligo dT16 2.5 µM 
dATP 1 mM 
dCTP 1 mM 
dGTP 1 mM 
dTTP 1 mM 
RNase inhibitor 1 U/µL 
MuLV Reverse Transcriptase 2.5 U/µL 
 
 
Real time PCR amplification steps were: pre-denaturation at 95°C for 10-min, 40 cycles 
of amplification with denaturation at 95°C for 15-sec, annealing at proper temperature 
for 60-sec and extension at 72°C for 30-sec. A final extension at 72°C for 10-min and a 
dissociation stage (95°C/60°C/95°C for 15-sec. each) was then added. GAPDH house-
keeping gene was used to normalize the relative mRNA amounts. 
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Table 5. Real Time PCR primers pair (cell cycle regulators). 
GenBank Number mRNA Primer pair TA (°C) 
Amplif. 
Region Length (bp) 
NM_001237 CCNA2 
(F) 5’-GAAGACGAGACGGGTTGCA-3’ 
(R) 5’-GAGATTCAGCTGGCTTCTTCTG-3’ 62 308-459 151 
NM_053056 CCND1 
(F) 5’-CCGTCCATGCGGAAGATC-3’ 
(R) 5’-CCTCCTCCTCGCACTTCTGT-3’ 62 369-438 70 
NM_001238 CCNE1 
(F) 5’-TGCCTGTACTGAGCTGGGCA-3’ 
(R) 5’-GGCTGCAGAAGAGGGTGTTG-3’ 60 497-608 112 
NM_001798 CDK2 
 (F) 5’-CAAGCTGCTGGATGTCATTC-3’ 
(R) 5’-AGCAGCTGGAACAGATAGCTCT-3’ 62 429-572 144 
NM_000389 CDKN1A 
(F) 5’-AGTGGACAGCGAGCAGCTGA-3’ 
(R) 5’-CGAAGTTCCATCGCTCACGG-3’ 62 166-248 83 
NM_004064 CDKN1B 
(F) 5’-CGGTGGACCACGAAGAGTTAA-3’ 
(R) 5’-GGCTCGCCTCTTCCATGTC-3’ 60 569-634 65 
NM_005225 E2F1 
(F) 5’-CCAGGAAAAGGTGTGAAATC-3’ 
(R) 5’-AAGCGCTTGGTGGTCAGATT-3’ 62 466-539 74 
NM_002046 GAPDH 
(F) 5’-CCCATCACCATCTTCCAGGAG-3’ 
(R) 5’-CTTCTCCATGGTGGTGAAGACG-3’ 60/62 319-423 105 
NM_205860 NR5A2 
(F) 5’-CCGACAAGTGGTACATGGAA-3’ 
(R) 5’-ACTCATGAGGTTGTTGAGGG-3’ 60 1382-1474 92 
NM_006221 PIN1 
(F) 5’-TTGAGTCTCTGGCCTCACAGTTCA-3’ 
(R) 5’-CAAACGAGGCGTCTTCAAATGGCT-3’ 60 308-418 110 
NM_000546 TP53 
(F) 5’-TACAAGCAGTCACAGCACATGACG-3’ 
(R) 5’-ACACGCAAATTTCCTTCCACTCGG-3’ 60 684-805 122 
 
 
4.17 Anti-E2F1 siRNA 
A preliminary selection of siRNAs was conducted according to previously reported 
guide lines [9, 10]. 
 
Anti-E2F1 siRNA (siE2F1) 
Sense strand: 5’-GAGGAGUUCAUCAGCCUUU-3’ 
Antisense strand: 5’-AAAGGCUGAUGAACUCCUC-3’ 
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As control a siRNA directed against the luciferase gene (siGL2) was analysed in 
parallel: 
Sense strand: 5’-CGUACGCGGAAUACUUCGA-3’ 
Antisense strand: 5’-UCGAAGUAUUCCGCGUACG-3’ 
 
For each cell line considered, uptake studies were previously performed using variable 
amounts of transfection reagent and siRNA conjugated with a fluorescent-isothiocyanate 
(FITC) molecule, in order to optimize the weight ratio of siRNA/transfection reagent. 
Transfection time was also optimized (1-6 hours), evaluating the amount of FITC 
positive cells using a fluorescence microscopic inspection (Leica Mycrosystem, Wetzlar, 
Germany). A quantitative evaluation of FITC positive transfected cells was carried out 
by flow cytometry (FACScanto, Becton Dickson, DIVA software) after cell 
trypsinization. 
The optimized transfection condition for HCC cells was 7.65 µg of liposome 
(Lipofectamin2000 – 1mg/mL, Invitrogen)  for HepG2 and 2.55 µg of liposome for 
HuH7 and JHH6 cells, mixed with 125 µl of medium (Optimem, Invitrogen) containing 
2.55 µg of the selected siRNAs and incubated for 15 minutes at room temperature. After 
20 min, necessary to allow liposome/siRNA complexes formation, the solution was 
added to 800 µl of DMEM High Glucose medium to reach a final siRNA concentration 
of 220 nM and then administered to HCC cells seeded in 96-wells plate at 4x103/well. 
After three hours of incubation the tranfection medium was replaced by a proper volume 
of complete medium and the cells maintained in culture for the indicated times. 
For the evaluation of the combined effects of siE2F1 and bortezomib, the cells were 
seeded in a 96-wells microtiter plate at 4x103/well. Following siE2F1 transfection, the 
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cells were incubated for one day with complete medium and then treated by 20 nM 
bortezomib and cultured for two days before performing the MTT viability assay. Each 
sample was analysed in triplicate.  
 
4.18 Two-color microarray-based gene expression analysis 
Two-color microarray-based gene expression analysis was performed according to 
Agilent Technologies protocol, using Agilent Scan B (supported with GenePix 4000B 
scanner and Feature Extraction software, version 9.5.3. – Agilent Technologies, USA). 
In particular, total RNA was extracted from cell cultures using RNeasy Mini kit (Qiagen 
S.p.A., Italy). The quality, integrity and quantification of total RNA were evaluated by 
spectrophotometric determination using a Lab-on-Chip-System Bioanalyzer 2100 
(Applera Corporation, USA) and a NanoDrop ND-1000 (CelBio, Euroclone, Italy). 
Fluorescent cRNA (complementary RNA) was created using Agilent’s Quick Amp 
Labeling Kit (Agilent Technologies, USA) with a sample input of total RNA of 200 ng. 
Complementary RNAs were purified using RNeasy Mini kit (Qiagen S.p.A., Italy) and 
quantification was performed using a NanoDrop ND-1000. According with Agilent 
protocol, for a 4x44K microarray, we used 825 ng of each cRNAs.  
 
4.19 Statistical analysis 
P values were calculated using the ANOVA one way test led by MS Excel. P values ≤ 
0.05 were considered to be statistically significant. 
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